Ingredient ID 360 
Chinese Pronunciation BAIFAN 
English Name Alum  
Latin Name Alumen  
Aliases ShiNie
Cancers Cervical  
Identified Compounds

order by name

1. Kal(so4)2.12h2o

   H24AlKO20S2   474.38

Recipes that contain
  1. 37      ChangAiShuan
  2. 268      ChangAiShuan
  3. 352      YuHuangWan
  4. 364      HuangBaiSan
  5. 419      WuHuDan
  6. 429      KangAiDan

Available references (order by impact factor):

1:  Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G.
Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
N Engl J Med.    impact factor:   28.857
2002;  347(21): 1652-61

2:  Gartner F, Alt FW, Monroe RJ, Seidl KJ.
Antigen-independent appearance of recombination activating gene (RAG)-positive bone marrow B cells in the spleens of immunized mice.
J Exp Med.    impact factor:   15.651
2000;  192(12): 1745-54

3:  Nagaoka H, Gonzalez-Aseguinolaza G, Tsuji M, Nussenzweig MC.
Immunization and infection change the number of recombination activating gene (RAG)-expressing B cells in the periphery by altering immature lymphocyte production.
J Exp Med.    impact factor:   15.651
2000;  191(12): 2113-20

4:  White H, Gray D.
Analysis of immunoglobulin (Ig) isotype diversity and IgM/D memory in the response to phenyl-oxazolone.
J Exp Med.    impact factor:   15.651
2000;  191(12): 2209-20

5:  Williams CM, Galli SJ.
Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice.
J Exp Med.    impact factor:   15.651
2000;  192(3): 455-62

6:  Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR.
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
J Natl Cancer Inst.    impact factor:   12.945
2001;  93(4): 284-92

7:  Sandstrom E, Wahren B.
Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group.
Lancet.    impact factor:   10.197
1999;  353(9166): 1735-42

8:  Chen Z, Koralov SB, Kelsoe G.
Regulation of humoral immune responses by CD21/CD35.
Immunol Rev.    impact factor:   7.27
2000;  176: 194-204

9:  Hotez PJ, Ghosh K, Hawdon JM, Narasimhan S, Jones B, Shuhua X, Sen L, Bin Z, Haechou X, Hainan R, Heng W, Koski RA.
Experimental approaches to the development of a recombinant hookworm vaccine.
Immunol Rev.    impact factor:   7.27
1999;  171: 163-71

10:  Lehner T, Bergmeier L, Wang Y, Tao L, Mitchell E.
A rational basis for mucosal vaccination against HIV infection.
Immunol Rev.    impact factor:   7.27
1999;  170: 183-96

11:  Deshmukh US, Kannapell CC, Fu SM.
Immune responses to small nuclear ribonucleoproteins: antigen-dependent distinct B cell epitope spreading patterns in mice immunized with recombinant polypeptides of small nuclear ribonucleoproteins.
J Immunol.    impact factor:   7.145
2002;  168(10): 5326-32

12:  Katagiri K, Zhang-Hoover J, Mo JS, Stein-Streilein J, Streilein JW.
Using tolerance induced via the anterior chamber of the eye to inhibit Th2-dependent pulmonary pathology.
J Immunol.    impact factor:   7.145
2002;  169(1): 84-9

13:  Taneichi M, Naito S, Kato H, Tanaka Y, Mori M, Nakano Y, Yamamura H, Ishida H, Komuro K, Uchida T.
T cell-independent regulation of IgE antibody production induced by surface-linked liposomal antigen.
J Immunol.    impact factor:   7.145
2002;  169(8): 4246-52

14:  Mayr SI, Zuberi RI, Zhang M, de Sousa-Hitzler J, Ngo K, Kuwabara Y, Yu L, Fung-Leung WP, Liu FT.
IgE-dependent mast cell activation potentiates airway responses in murine asthma models.
J Immunol.    impact factor:   7.145
2002;  169(4): 2061-8

15:  Tournoy KG, Kips JC, Pauwels RA.
The allergen-induced airway hyperresponsiveness in a human-mouse chimera model of asthma is T cell and IL-4 and IL-5 dependent.
J Immunol.    impact factor:   7.145
2001;  166(11): 6982-91

16:  Kilmon MA, Ghirlando R, Strub MP, Beavil RL, Gould HJ, Conrad DH.
Regulation of IgE production requires oligomerization of CD23.
J Immunol.    impact factor:   7.145
2001;  167(6): 3139-45

17:  Kim Y, Sung Ss, Kuziel WA, Feldman S, Fu SM, Rose CE Jr.
Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2).
J Immunol.    impact factor:   7.145
2001;  166(8): 5183-92

18:  Jilek S, Barbey C, Spertini F, Corthesy B.
Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice.
J Immunol.    impact factor:   7.145
2001;  166(5): 3612-21

19:  Zuberi RI, Apgar JR, Chen SS, Liu FT.
Role for IgE in airway secretions: IgE immune complexes are more potent inducers than antigen alone of airway inflammation in a murine model.
J Immunol.    impact factor:   7.145
2000;  164(5): 2667-73

20:  Alexander J, del Guercio MF, Maewal A, Qiao L, Fikes J, Chesnut RW, Paulson J, Bundle DR, DeFrees S, Sette A.
Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses.
J Immunol.    impact factor:   7.145
2000;  164(3): 1625-33

21:  Kobayashi T, Miura T, Haba T, Sato M, Serizawa I, Nagai H, Ishizaka K.
An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model.
J Immunol.    impact factor:   7.145
2000;  164(7): 3855-61

22:  Chen Z, Koralov SB, Gendelman M, Carroll MC, Kelsoe G.
Humoral immune responses in Cr2-/- mice: enhanced affinity maturation but impaired antibody persistence.
J Immunol.    impact factor:   7.145
2000;  164(9): 4522-32

23:  Applequist SE, Dahlstrom J, Jiang N, Molina H, Heyman B.
Antibody production in mice deficient for complement receptors 1 and 2 can be induced by IgG/Ag and IgE/Ag, but not IgM/Ag complexes.
J Immunol.    impact factor:   7.145
2000;  165(5): 2398-403

24:  Wu X, Jiang N, Fang YF, Xu C, Mao D, Singh J, Fu YX, Molina H.
Impaired affinity maturation in Cr2-/- mice is rescued by adjuvants without improvement in germinal center development.
J Immunol.    impact factor:   7.145
2000;  165(6): 3119-27

25:  Cottrez F, Hurst SD, Coffman RL, Groux H.
T regulatory cells 1 inhibit a Th2-specific response in vivo.
J Immunol.    impact factor:   7.145
2000;  165(9): 4848-53

26:  Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, Heeger PS, Trezza RP, Heinzel FP, Forsthuber T, Lehmann PV.
Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response.
J Immunol.    impact factor:   7.145
1999;  162(7): 3942-9

27:  Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K.
Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.
J Immunol.    impact factor:   7.145
1999;  163(8): 4481-8

28:  Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J.
Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling.
J Immunol.    impact factor:   7.145
1999;  163(12): 6448-54

29:  Payet ME, Woodward EC, Conrad DH.
Humoral response suppression observed with CD23 transgenics.
J Immunol.    impact factor:   7.145
1999;  163(1): 217-23

30:  Fernando GJ, Stewart TJ, Tindle RW, Frazer IH.
Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
J Immunol.    impact factor:   7.145
1998;  161(5): 2421-7

31:  Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, Weeranta R.
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
J Immunol.    impact factor:   7.145
1998;  160(2): 870-6

32:  MacAry PA, Holmes BJ, Kemeny DM.
Ovalbumin-specific, MHC class I-restricted, alpha beta-positive, Tc1 and Tc0 CD8+ T cell clones mediate the in vivo inhibition of rat IgE.
J Immunol.    impact factor:   7.145
1998;  160(2): 580-7

33:  Comoy EE, Pestel J, Duez C, Stewart GA, Vendeville C, Fournier C, Finkelman F, Capron A, Thyphronitis G.
The house dust mite allergen, Dermatophagoides pteronyssinus, promotes type 2 responses by modulating the balance between IL-4 and IFN-gamma.
J Immunol.    impact factor:   7.145
1998;  160(5): 2456-62

34:  Pontesilli O, Guerra EC, Ammassari A, Tomino C, Carlesimo M, Antinori A, Tamburrini E, Prozzo A, Seeber AC, Vella S, Ortona L, Aiuti F.
Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
AIDS.    impact factor:   6.931
1998;  12(5): 473-80

35:  Kelleher AD, Roggensack M, Jaramillo AB, Smith DE, Walker A, Gow I, McMurchie M, Harris J, Patou G, Cooper DA.
Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
AIDS.    impact factor:   6.931
1998;  12(2): 175-82

36:  Serth J, Kuczyk MA, Paeslack U, Lichtinghagen R, Jonas U.
Quantitation of DNA extracted after micropreparation of cells from frozen and formalin-fixed tissue sections.
Am J Pathol.    impact factor:   6.436
2000;  156(4): 1189-96

37:  De Swart RL, Kuiken T, Timmerman HH, Amerongen Gv G, Van Den Hoogen BG, Vos HW, Neijens HJ, Andeweg AC, Osterhaus AD.
Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection.
J Virol.    impact factor:   5.93
2002;  76(22): 11561-9

38:  Plotnicky-Gilquin H, Cyblat-Chanal D, Aubry JP, Champion T, Beck A, Nguyen T, Bonnefoy JY, Corvaia N.
Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.
J Virol.    impact factor:   5.93
2002;  76(20): 10203-10

39:  Power UF, Huss T, Michaud V, Plotnicky-Gilquin H, Bonnefoy JY, Nguyen TN.
Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.
J Virol.    impact factor:   5.93
2001;  75(24): 12421-30

40:  Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM.
A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans.
J Virol.    impact factor:   5.93
1999;  73(7): 5903-11

41:  McCluskie MJ, Davis HL.
Novel strategies using DNA for the induction of mucosal immunity.
Crit Rev Immunol.    impact factor:   5.726
1999;  19(4): 303-29

42:  Spack EG.
Treatment of autoimmune diseases through manipulation of antigen presentation.
Crit Rev Immunol.    impact factor:   5.726
1997;  17(5-6): 529-36

43:  Schallert N, Pihlgren M, Kovarik J, Roduit C, Tougne C, Bozzotti P, Del Giudice G, Siegrist CA, Lambert PH.
Generation of adult-like antibody avidity profiles after early-life immunization with protein vaccines.
Eur J Immunol.    impact factor:   5.635
2002;  32(3): 752-60

44:  von Garnier C, Astori M, Kettner A, Dufour N, Heusser C, Corradin G, Spertini F.
Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis.
Eur J Immunol.    impact factor:   5.635
2000;  30(6): 1638-45

45:  Lehner T, Mitchell E, Bergmeier L, Singh M, Spallek R, Cranage M, Hall G, Dennis M, Villinger F, Wang Y.
The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection.
Eur J Immunol.    impact factor:   5.635
2000;  30(8): 2245-56

46:  Wu XM, Nakashima M, Watanabe T.
Selective suppression of antigen-specific Th2 cells by continuous micro-dose oral tolerance.
Eur J Immunol.    impact factor:   5.635
1998;  28(1): 134-42

47:  Lambert AL, Winsett DW, Costa DL, Selgrade MK, Gilmour MI.
Transfer of allergic airway responses with serum and lymphocytes from rats sensitized to dust mite.
Am J Respir Crit Care Med.    impact factor:   5.491
1998;  157(6 Pt 1): 1991-9

48:  Cho SH, Strickland I, Tomkinson A, Fehringer AP, Gelfand EW, Leung DY.
Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model.
J Invest Dermatol.    impact factor:   4.903
2001;  116(5): 658-63

49:  Sohn S, Lee ES, Kwon HJ, Lee SI, Bang D, Lee S.
Expression of Th2 cytokines decreases the development of and improves Behcet's disease-like symptoms induced by herpes simplex virus in mice.
J Infect Dis.    impact factor:   4.842
2001;  183(8): 1180-6

50:  Bungiro RD Jr, Greene J, Kruglov E, Cappello M.
Mitigation of hookworm disease by immunization with soluble extracts of Ancylostoma ceylanicum.
J Infect Dis.    impact factor:   4.842
2001;  183(9): 1380-7

51:  Peebles RS Jr, Sheller JR, Collins RD, Jarzecka K, Mitchell DB, Graham BS.
Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.
J Infect Dis.    impact factor:   4.842
2000;  182(3): 671-7

52:  Nardin EH, Oliveira GA, Calvo-Calle JM, Castro ZR, Nussenzweig RS, Schmeckpeper B, Hall BF, Diggs C, Bodison S, Edelman R.
Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes.
J Infect Dis.    impact factor:   4.842
2000;  182(5): 1486-96

53:  Siegrist CA, Plotnicky-Gilquin H, Cordova M, Berney M, Bonnefoy JY, Nguyen TN, Lambert PH, Power UF.
Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies.
J Infect Dis.    impact factor:   4.842
1999;  179(6): 1326-33

54:  Ghosh K, Hotez PJ.
Antibody-dependent reductions in mouse hookworm burden after vaccination with Ancylostoma caninum secreted protein 1.
J Infect Dis.    impact factor:   4.842
1999;  180(5): 1674-81

55:  Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL.
A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
J Infect Dis.    impact factor:   4.842
1999;  180(4): 970-5

56:  Zheng W, Maye MM, Leibowitz FL, Zhong CJ.
Imparting biomimetic ion-gating recognition properties to electrodes with a hydrogen-bonding structured core-shell nanoparticle network.
Anal Chem.    impact factor:   4.555
2000;  72(10): 2190-9

57:  Kanwar S, Smith CW, Shardonofsky FR, Burns AR.
The role of Mac-1 (CD11b/CD18) in antigen-induced airway eosinophilia in mice.
Am J Respir Cell Mol Biol.    impact factor:   4.541
2001;  25(2): 170-7

58:  Wilder JA, Collie DD, Wilson BS, Bice DE, Lyons CR, Lipscomb MF.
Dissociation of airway hyperresponsiveness from immunoglobulin E and airway eosinophilia in a murine model of allergic asthma.
Am J Respir Cell Mol Biol.    impact factor:   4.541
1999;  20(6): 1326-34

59:  Hamelmann E, Takeda K, Schwarze J, Vella AT, Irvin CG, Gelfand EW.
Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes.
Am J Respir Cell Mol Biol.    impact factor:   4.541
1999;  21(4): 480-9

60:  Richards KD, Schott EJ, Sharma YK, Davis KR, Gardner RC.
Aluminum induces oxidative stress genes in Arabidopsis thaliana.
Plant Physiol.    impact factor:   4.434
1998;  116(1): 409-18

61:  Bantel C, Childers SR, Eisenach JC.
Role of adenosine receptors in spinal G-protein activation after peripheral nerve injury.
Anesthesiology.    impact factor:   4.265
2002;  96(6): 1443-9

62:  Tabatabaei M, Liu Z, Finucane A, Parton R, Coote J.
Protective immunity conferred by attenuated aroA derivatives of Pasteurella multocida B:2 strains in a mouse model of hemorrhagic septicemia.
Infect Immun.    impact factor:   4.184
2002;  70(7): 3355-62

63:  Near KA, Stowers AW, Jankovic D, Kaslow DC.
Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.
Infect Immun.    impact factor:   4.184
2002;  70(2): 692-701

64:  Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB.
Immunogenicity of a 26-valent group A streptococcal vaccine.
Infect Immun.    impact factor:   4.184
2002;  70(4): 2171-7

65:  Pal S, Davis HL, Peterson EM, de la Maza LM.
Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge.
Infect Immun.    impact factor:   4.184
2002;  70(9): 4812-7

66:  Londono-Arcila P, Freeman D, Kleanthous H, O'Dowd AM, Lewis S, Turner AK, Rees EL, Tibbitts TJ, Greenwood J, Monath TP, Darsley MJ.
Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen.
Infect Immun.    impact factor:   4.184
2002;  70(9): 5096-106

67:  Abraham D, Leon O, Leon S, Lustigman S.
Development of a recombinant antigen vaccine against infection with the filarial worm Onchocerca volvulus.
Infect Immun.    impact factor:   4.184
2001;  69(1): 262-70

68:  Kotloff KL, Wasserman SS, Losonsky GA, Thomas W Jr, Nichols R, Edelman R, Bridwell M, Monath TP.
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.
Infect Immun.    impact factor:   4.184
2001;  69(2): 988-95

69:  Smith DJ, King WF, Barnes LA, Trantolo D, Wise DL, Taubman MA.
Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines.
Infect Immun.    impact factor:   4.184
2001;  69(8): 4767-73

70:  Scharf O, Agranovich I, Lee K, Eller NL, Levy L, Inman J, Scott DE, Golding B.
Ontogeny of Th1 memory responses against a Brucella abortus conjugate.
Infect Immun.    impact factor:   4.184
2001;  69(9): 5417-22

71:  Paoletti LC, Rench MA, Kasper DL, Molrine D, Ambrosino D, Baker CJ.
Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
Infect Immun.    impact factor:   4.184
2001;  69(11): 6696-701

72:  Krishnan L, Dicaire CJ, Patel GB, Sprott GD.
Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum.
Infect Immun.    impact factor:   4.184
2000;  68(1): 54-63

73:  Tuo W, Palmer GH, McGuire TC, Zhu D, Brown WC.
Interleukin-12 as an adjuvant promotes immunoglobulin G and type 1 cytokine recall responses to major surface protein 2 of the ehrlichial pathogen Anaplasma marginale.
Infect Immun.    impact factor:   4.184
2000;  68(1): 270-80

74:  Yang C, Collins WE, Sullivan JS, Kaslow DC, Xiao L, Lal AA.
Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.
Infect Immun.    impact factor:   4.184
1999;  67(1): 342-9

75:  Chen Y, Boros DL.
Polarization of the immune response to the single immunodominant epitope of p38, a major Schistosoma mansoni egg antigen, generates Th1- or Th2-type cytokines and granulomas.
Infect Immun.    impact factor:   4.184
1999;  67(9): 4570-7

76:  Ryan EJ, McNeela E, Murphy GA, Stewart H, O'hagan D, Pizza M, Rappuoli R, Mills KH.
Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
Infect Immun.    impact factor:   4.184
1999;  67(12): 6270-80

77:  Bungiro RD Jr, Goldberg M, Suri PK, Knopf PM.
Interleukin-12 as an adjuvant for an antischistosome vaccine consisting of adult worm antigens: protection of rats from cercarial challenge.
Infect Immun.    impact factor:   4.184
1999;  67(5): 2340-8

78:  Bakaletz LO, Kennedy BJ, Novotny LA, Duquesne G, Cohen J, Lobet Y.
Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection.
Infect Immun.    impact factor:   4.184
1999;  67(6): 2746-62

79:  Stacey KJ, Blackwell JM.
Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
Infect Immun.    impact factor:   4.184
1999;  67(8): 3719-26

80:  Agranovich I, Scott DE, Terle D, Lee K, Golding B.
Down-regulation of Th2 responses by Brucella abortus, a strong Th1 stimulus, correlates with alterations in the B7.2-CD28 pathway.
Infect Immun.    impact factor:   4.184
1999;  67(9): 4418-26

81:  Singh Y, Ivins BE, Leppla SH.
Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis.
Infect Immun.    impact factor:   4.184
1998;  66(7): 3447-8

82:  Wortham C, Grinberg L, Kaslow DC, Briles DE, McDaniel LS, Lees A, Flora M, Snapper CM, Mond JJ.
Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2.
Infect Immun.    impact factor:   4.184
1998;  66(4): 1513-20

83:  McCluskie MJ, Weeratna RD, Davis HL.
Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution.
Mol Med.    impact factor:   4.155
2000;  6(10): 867-77

84:  Gramzinski RA, Millan CL, Obaldia N, Hoffman SL, Davis HL.
Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration.
Mol Med.    impact factor:   4.155
1998;  4(2): 109-18

85:  Campbell A, Prasad KN, Bondy SC.
Aluminum-induced oxidative events in cell lines: glioma are more responsive than neuroblastoma.
Free Radic Biol Med.    impact factor:   4.116
1999;  26(9-10): 1166-71

86:  Xiao C, Wesolowski DJ, Palmer DA.
Formation quotients of aluminum sulfate complexes in NaCF3SO3 media at 10, 25, and 50 degrees C from potentiometric titrations using a mercury/mercurous sulfate electrode concentration cell.
Environ Sci Technol.    impact factor:   3.751
2002;  36(2): 166-73

87:  Peak D, Sims JT, Sparks DL.
Solid-state speciation of natural and alum-amended poultry litter using XANES spectroscopy.
Environ Sci Technol.    impact factor:   3.751
2002;  36(20): 4253-61

88:  McCubbin DR, Apelberg BJ, Roe S, Divita F Jr.
Livestock ammonia management and particulate-related health benefits.
Environ Sci Technol.    impact factor:   3.751
2002;  36(6): 1141-6

89:  Lo IMC, Lai KC, Chen GH.
Salinity effect on mechanical dewatering of sludge with and without chemical conditioning.
Environ Sci Technol.    impact factor:   3.751
2001;  35(23): 4691-6

90:  Fukasawa M, Shimizu Y, Shikata K, Nakata M, Sakakibara R, Yamamoto N, Hatanaka M, Mizuochi T.
Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes.
FEBS Lett.    impact factor:   3.72
1998;  441(3): 353-6

91:  Staib L, Birebent B, Somasundaram R, Purev E, Braumuller H, Leeser C, Kuttner N, Li W, Zhu D, Diao J, Wunner W, Speicher D, Beger HG, Song H, Herlyn D.
Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients.
Int J Cancer.    impact factor:   3.545
2001;  92(1): 79-87

92:  Katz CS.
Humoral antibody formation in infants aged one to three months injected with a triple (diphtheria-tetanus-pertussis) alum-precipitated antigen, by William L. Bradford, MD, et al, Pediatrics, 1949;4:711-718.
Pediatrics.    impact factor:   3.487
1998;  102(1 Pt 2): 207-9

93:  Wagner U, Kohler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Mobus V, Kreienberg R, Bauknecht T, Krebs D, Wallwiener D.
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001.
Clin Cancer Res.    impact factor:   3.442
2001;  7(5): 1154-62

94:  Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF.
Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Clin Cancer Res.    impact factor:   3.442
2001;  7(7): 1882-7

95:  Axelson O, Fredrikson M, Akerblom G, Hardell L.
Leukemia in childhood and adolescence and exposure to ionizing radiation in homes built from uranium-containing alum shale concrete.
Epidemiology.    impact factor:   3.377
2002;  13(2): 146-50

96:  Notka F, Stahl-Hennig C, Dittmer U, Wolf H, Wagner R.
Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model.
Biol Chem.    impact factor:   3.356
1999;  380(3): 341-52

97:  Koetzner L, Deng S, Sumpter TL, Weisslitz M, Abner RT, Landry DW, Woods JH.
Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys.
J Pharmacol Exp Ther.    impact factor:   3.3
2001;  296(3): 789-96

98:  Backer H.
Water disinfection for international and wilderness travelers.
Clin Infect Dis.    impact factor:   3.199
2002;  34(3): 355-64

99:  Rosas JE, Pedraz JL, Hernandez RM, Gascon AR, Igartua M, Guzman F, Rodriguez R, Cortes J, Patarroyo ME.
Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres.
Vaccine.    impact factor:   3.173
2002;  20(13-14): 1707-10

100:  Schijns VE, Scholtes NC, Zuilekom HI, Sanders LE, Nicolson L, Argyle DJ.
Facilitation of antibody forming responses to viral vaccine antigens in young cats by recombinant baculovirus-expressed feline IFN-gamma.
Vaccine.    impact factor:   3.173
2002;  20(13-14): 1718-24

101:  Lofthouse SA, Kajihara M, Nagahara S, Nash A, Barcham GJ, Sedgmen B, Brandon MR, Sano A.
Injectable silicone implants as vaccine delivery vehicles.
Vaccine.    impact factor:   3.173
2002;  20(13-14): 1725-32

102:  Peng HJ, Su SN, Chang ZN, Chao PL, Kuo SW, Tsai LC.
Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f 11.
Vaccine.    impact factor:   3.173
2002;  20(13-14): 1761-8

103:  Kashala O, Amador R, Valero MV, Moreno A, Barbosa A, Nickel B, Daubenberger CA, Guzman F, Pluschke G, Patarroyo ME.
Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.
Vaccine.    impact factor:   3.173
2002;  20(17-18): 2263-77

104:  Klinguer-Hamour C, Libon C, Plotnicky-Gilquin H, Bussat MC, Revy L, Nguyen T, Bonnefoy JY, Corvaia N, Beck A.
DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine.
Vaccine.    impact factor:   3.173
2002;  20(21-22): 2743-51

105:  Desombere I, Van der Wielen M, Van Damme P, Stoffel M, De Clercq N, Goilav C, Leroux-Roels G.
Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant.
Vaccine.    impact factor:   3.173
2002;  20(19-20): 2597-602

106:  Suenobu N, Kweon MN, Kiyono H.
Nasal vaccination induces the ability to eliminate Candida colonization without influencing the pre-existing antigen-specific IgE Abs: a possibility for the control of Candida-related atopic dermatitis.
Vaccine.    impact factor:   3.173
2002;  20(23-24): 2972-80

107:  Rankin R, Pontarollo R, Gomis S, Karvonen B, Willson P, Loehr BI, Godson DL, Babiuk LA, Hecker R, van Drunen Littel-van den Hurk S.
CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D.
Vaccine.    impact factor:   3.173
2002;  20(23-24): 3014-22

108:  Baylor NW, Egan W, Richman P.
Aluminum salts in vaccines--US perspective.
Vaccine.    impact factor:   3.173
2002;  20 Suppl 3: S18-23

109:  Dargeviciute A, Brus Sjolander K, Sasnauskas K, Kruger DH, Meisel H, Ulrich R, Lundkvist A.
Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model.
Vaccine.    impact factor:   3.173
2002;  20(29-30): 3523-31

110:  Jacques P, Moens G, Desombere I, Dewijngaert J, Leroux-Roels G, Wettendorff M, Thoelen S.
The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
Vaccine.    impact factor:   3.173
2002;  20(31-32): 3644-9

111:  Vernacchio L, Bernstein H, Pelton S, Allen C, MacDonald K, Dunn J, Duncan DD, Tsao G, LaPosta V, Eldridge J, Laussucq S, Ambrosino DM, Molrine DC.
Effect of monophosphoryl lipid A (MPL on T-helper cells when administered as an adjuvant with pneumocococcal-CRM(197) conjugate vaccine in healthy toddlers.
Vaccine.    impact factor:   3.173
2002;  20(31-32): 3658-67

112:  Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL.
Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.
Vaccine.    impact factor:   3.173
2002;  21(1-2): 67-77

113:  Kemp JM, Kajihara M, Nagahara S, Sano A, Brandon M, Lofthouse S.
Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses.
Vaccine.    impact factor:   3.173
2002;  20(7-8): 1089-98

114:  Cianciolo GJ, Enghild JJ, Pizzo SV.
Covalent complexes of antigen and alpha(2)-macroglobulin: evidence for dramatically-increased immunogenicity.
Vaccine.    impact factor:   3.173
2001;  20(3-4): 554-62

115:  Cunha MG, Rodrigues MM, Soares IS.
Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP1(19) expressed in distinct bacterial vectors.
Vaccine.    impact factor:   3.173
2001;  20(3-4): 385-96

116:  Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, Belshe R, Graham BS, Spearman PW, Schwartz D, Mulligan MJ, Goepfert P, Fast P, Berman P, Powell M, Francis D.
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
Vaccine.    impact factor:   3.173
2001;  19(15-16): 2080-91

117:  Thoelen S, De Clercq N, Tornieporth N.
A prophylactic hepatitis B vaccine with a novel adjuvant system.
Vaccine.    impact factor:   3.173
2001;  19(17-19): 2400-3

118:  Chen D, Erickson CA, Endres RL, Periwal SB, Chu Q, Shu C, Maa YF, Payne LG.
Adjuvantation of epidermal powder immunization.
Vaccine.    impact factor:   3.173
2001;  19(20-22): 2908-17

119:  Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W.
A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.
Vaccine.    impact factor:   3.173
2001;  19(23-24): 3033-42

120:  Higaki M, Azechi Y, Takase T, Igarashi R, Nagahara S, Sano A, Fujioka K, Nakagawa N, Aizawa C, Mizushima Y.
Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid.
Vaccine.    impact factor:   3.173
2001;  19(23-24): 3091-6

121:  Gupta A, Pal R, Ahlawat S, Bhatia P, Singh O.
Enhanced immunogenicity of a contraceptive vaccine using diverse synthetic carriers with permissible adjuvant.
Vaccine.    impact factor:   3.173
2001;  19(25-26): 3384-9

122:  Misra A, Dube A, Srivastava B, Sharma P, Srivastava JK, Katiyar JC, Naik S.
Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG.
Vaccine.    impact factor:   3.173
2001;  19(25-26): 3485-92

123:  Palker TJ, Monteiro JM, Martin MM, Kakareka C, Smith JF, Cook JC, Joyce JG, Jansen KU.
Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles.
Vaccine.    impact factor:   3.173
2001;  19(27): 3733-43

124:  Diwan M, Khar RK, Talwar GP.
Tetanus toxoid loaded 'preformed microspheres' of cross-linked dextran.
Vaccine.    impact factor:   3.173
2001;  19(28-29): 3853-9

125:  Lofthouse S, Nagahara S, Sedgmen B, Barcham G, Brandon M, Sano A.
The application of biodegradable collagen minipellets as vaccine delivery vehicles in mice and sheep.
Vaccine.    impact factor:   3.173
2001;  19(30): 4318-27

126:  Rosas JE, Hernandez RM, Gascon AR, Igartua M, Guzman F, Patarroyo ME, Pedraz JL.
Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.
Vaccine.    impact factor:   3.173
2001;  19(31): 4445-51

127:  Scheifele DW, Halperin SA, Ferguson AC.
Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens.
Vaccine.    impact factor:   3.173
2001;  19(32): 4720-6

128:  Zimmerman DH, Lloyd JP, Heisey D, Winship MD, Siwek M, Talor E, Sarin PS.
Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain.
Vaccine.    impact factor:   3.173
2001;  19(32): 4750-9

129:  Villarreal-Ramos B, Manser JM, Collins RA, Dougan G, Howard CJ.
Cattle immune responses to tetanus toxoid elicited by recombinant S. typhimurium vaccines or tetanus toxoid in alum or Freund's adjuvant.
Vaccine.    impact factor:   3.173
2000;  18(15): 1515-21

130:  McCormack S, Tilzey A, Carmichael A, Gotch F, Kepple J, Newberry A, Jones G, Lister S, Beddows S, Cheingsong R, Rees A, Babiker A, Banatvala J, Bruck C, Darbyshire J, Tyrrell D, Van Hoecke C, Weber J.
A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.
Vaccine.    impact factor:   3.173
2000;  18(13): 1166-77

131:  Weeratna RD, McCluskie MJ, Xu Y, Davis HL.
CpG DNA induces stronger immune responses with less toxicity than other adjuvants.
Vaccine.    impact factor:   3.173
2000;  18(17): 1755-62

132:  Eberl M, Beck E, Coulson PS, Okamura H, Wilson RA, Mountford AP.
IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen.
Vaccine.    impact factor:   3.173
2000;  18(19): 2002-8

133:  Argiro L, Henri S, Dessein H, Kouriba B, Dessein AJ, Bourgois A.
Induction of a protection against S. mansoni with a MAP containing epitopes of Sm37-GAPDH and Sm10-DLC. Effect of coadsorption with GM-CSF on alum.
Vaccine.    impact factor:   3.173
2000;  18(19): 2033-8

134:  Ambrosch F, Wiedermann G, Kundi M, Leroux-Roels G, Desombere I, Garcon N, Thiriart C, Slaoui M, Thoelen S.
A hepatitis B vaccine formulated with a novel adjuvant system.
Vaccine.    impact factor:   3.173
2000;  18(20): 2095-101

135:  Sen L, Ghosh K, Bin Z, Qiang S, Thompson MG, Hawdon JM, Koski RA, Shuhua X, Hotez PJ.
Hookworm burden reductions in BALB/c mice vaccinated with recombinant Ancylostoma secreted proteins (ASPs) from Ancylostoma duodenale, Ancylostoma caninum and Necator americanus.
Vaccine.    impact factor:   3.173
2000;  18(11-12): 1096-102

136:  Perraut R, Morales-Betoulle S, Le Scanf C, Bourreau E, Guillotte M, Bonnefoy S, Michel J, Mercereau-Puijalon O.
Evaluation of immunogenicity and protective efficacy of carrier-free Plasmodium falciparum R23 antigen in pre-exposed saimiri sciureus monkeys.
Vaccine.    impact factor:   3.173
2000;  19(1): 59-67

137:  Argiro L, Henri S, Dessein H, Kouriba B, Dessein AJ, Bourgois A.
Induction of a protection against S. mansoni with a MAP containing epitopes of Sm37-GAPDH and Sm10-DLC. Effect of coadsorbtion with GM-CSF on alum.
Vaccine.    impact factor:   3.173
2000;  18(19): 2033-2038

138:  Johansen P, Estevez F, Zurbriggen R, Merkle HP, Gluck R, Corradin G, Gander B.
Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres.
Vaccine.    impact factor:   3.173
2000;  19(9-10): 1047-54

139:  McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, Peppoloni S, Rappuoli R, Mills KH.
A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery.
Vaccine.    impact factor:   3.173
2000;  19(9-10): 1188-98

140:  Wrightsman RA, Manning JE.
Paraflagellar rod proteins administered with alum and IL-12 or recombinant adenovirus expressing IL-12 generates antigen-specific responses and protective immunity in mice against Trypanosoma cruzi.
Vaccine.    impact factor:   3.173
2000;  18(14): 1419-27

141:  Chen H, Nara T, Zeng X, Satoh M, Wu G, Jiang W, Yi F, Kojima S, Zhang S, Hirayama K.
Vaccination of domestic pig with recombinant paramyosin. against Schistosoma japonicum in China.
Vaccine.    impact factor:   3.173
2000;  18(20): 2142-6

142:  Lee CK, Soike K, Giannasca P, Hill J, Weltzin R, Kleanthous H, Blanchard J, Monath TP.
Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori.
Vaccine.    impact factor:   3.173
1999;  17(23-24): 3072-82

143:  Katayama S, Oda K, Ohgitani T, Hirahara T, Shimizu Y.
Influence of antigenic forms and adjuvants on the IgG subclass antibody response to Aujeszky's disease virus in mice.
Vaccine.    impact factor:   3.173
1999;  17(20-21): 2733-9

144:  Raya NE, Quintana D, Carrazana Y, Gomez CE, Duarte CA.
A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9.
Vaccine.    impact factor:   3.173
1999;  17(20-21): 2646-50

145:  Coombes AG, Lavelle EC, Davis SS.
Biodegradable lamellar particles of poly(lactide) induce sustained immune responses to a single dose of adsorbed protein.
Vaccine.    impact factor:   3.173
1999;  17(19): 2410-22

146:  Schroder U, Svenson SB.
Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants.
Vaccine.    impact factor:   3.173
1999;  17(15-16): 2096-103

147:  Schedel I, Sutor GC, Hunsmann G, Jurkiewicz E.
Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers.
Vaccine.    impact factor:   3.173
1999;  17(15-16): 1837-45

148:  Wang Y, Tao L, Mitchell E, Bergmeier L, Doyle C, Lehner T.
The effect of immunization on chemokines and CCR5 and CXCR4 coreceptor functions in SIV binding and chemotaxis.
Vaccine.    impact factor:   3.173
1999;  17(15-16): 1826-36

149:  McInerney TL, Brennan FR, Jones TD, Dimmock NJ.
Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide.
Vaccine.    impact factor:   3.173
1999;  17(11-12): 1359-68

150:  Zurbriggen R, Gluck R.
Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice.
Vaccine.    impact factor:   3.173
1999;  17(11-12): 1301-5

151:  Gluck R.
Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs).
Vaccine.    impact factor:   3.173
1999;  17(13-14): 1782-7

152:  Argiro L, Henri S, Dessein H, Dessein AJ, Bourgois A.
Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum.
Vaccine.    impact factor:   3.173
1999;  17(1): 13-8

153:  Larsson C, Stalhammar-Carlemalm M, Lindahl G.
Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine.
Vaccine.    impact factor:   3.173
1999;  17(5): 454-8

154:  West K, Petrie L, Haines DM, Konoby C, Clark EG, Martin K, Ellis JA.
The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection in calves.
Vaccine.    impact factor:   3.173
1999;  17(7-8): 809-20

155:  Rajananthanan P, Attard GS, Sheikh NA, Morrow WJ.
Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses.
Vaccine.    impact factor:   3.173
1999;  17(7-8): 715-30

156:  Dale JB.
Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.
Vaccine.    impact factor:   3.173
1999;  17(2): 193-200

157:  Lian T, Bui T, Ho RJ.
Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses.
Vaccine.    impact factor:   3.173
1999;  18(7-8): 604-11

158:  Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, Krzych U, Palmer DR, Egan A, Diggs C, Ballou WR, Hall BF, Kaslow D.
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid.
Vaccine.    impact factor:   3.173
1999;  18(5-6): 531-9

159:  Dupuis M, McDonald DM, Ott G.
Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice.
Vaccine.    impact factor:   3.173
1999;  18(5-6): 434-9

160:  Notka F, Stahl-Hennig C, Dittmer U, Wolf H, Wagner R.
Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies.
Vaccine.    impact factor:   3.173
1999;  18(3-4): 291-301

161:  Jabbal-Gill I, Lin W, Jenkins P, Watts P, Jimenez M, Illum L, Davis SS, Wood JM, Major D, Minor PD, Li X, Lavelle EC, Coombes AG.
Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines.
Vaccine.    impact factor:   3.173
1999;  18(3-4): 238-50

162:  Johansen P, Moon L, Tamber H, Merkle HP, Gander B, Sesardic D.
Immunogenicity of single-dose diphtheria vaccines based on PLA/PLGA microspheres in guinea pigs.
Vaccine.    impact factor:   3.173
1999;  18(3-4): 209-15

163:  Moreno CA, Rodriguez R, Oliveira GA, Ferreira V, Nussenzweig RS, Moya Castro ZR, Calvo-Calle JM, Nardin E.
Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.
Vaccine.    impact factor:   3.173
1999;  18(1-2): 89-99

164:  Diminsky D, Moav N, Gorecki M, Barenholz Y.
Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles.
Vaccine.    impact factor:   3.173
1999;  18(1-2): 3-17

165:  Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WR, Reber R, Sturchler D.
Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant.
Vaccine.    impact factor:   3.173
1999;  17(23-24): 3145-59

166:  Koike Y, Yoo YC, Mitobe M, Oka T, Okuma K, Tono-oka S, Azuma I.
Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
Vaccine.    impact factor:   3.173
1998;  16(20): 1982-9

167:  Nelson KM, Schram BR, McGregor MW, Sheoran AS, Olsen CW, Lunn DP.
Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination.
Vaccine.    impact factor:   3.173
1998;  16(13): 1306-13

168:  Petersen E, Nielsen HV, Christiansen L, Spenter J.
Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii.
Vaccine.    impact factor:   3.173
1998;  16(13): 1283-9

169:  Verma R, Jaiswal TN.
Haemorrhagic septicaemia vaccines.
Vaccine.    impact factor:   3.173
1998;  16(11-12): 1184-92

170:  Ferro VA, Stimson WH.
Investigation into suitable carrier molecules for use in an anti-gonadotrophin releasing hormone vaccine.
Vaccine.    impact factor:   3.173
1998;  16(11-12): 1095-102

171:  Demicheli V, Rivetti D, Deeks JJ, Jefferson T, Pratt M.
The effectiveness and safety of vaccines against human anthrax: a systematic review.
Vaccine.    impact factor:   3.173
1998;  16(9-10): 880-4

172:  Nardin EH, Calvo-Calle JM, Oliveira GA, Clavijo P, Nussenzweig R, Simon R, Zeng W, Rose K.
Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein.
Vaccine.    impact factor:   3.173
1998;  16(6): 590-600

173:  Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, O'Hagan DT.
Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models.
Vaccine.    impact factor:   3.173
1998;  16(4): 346-52

174:  van Scott MR, Justice JP, Bradfield JF, Enright E, Sigounas A, Sur S.
IL-10 reduces Th2 cytokine production and eosinophilia but augments airway reactivity in allergic mice.
Am J Physiol Lung Cell Mol Physiol.    impact factor:   3.147
2000;  278(4): L667-74

175:  Diwan M, Dawar H, Talwar GP.
Induction of early and bioeffective antibody response in rodents with the luteinizing hormone-releasing hormone vaccine given as a single dose in biodegradable microspheres along with alum.
Prostate.    impact factor:   3.037
1998;  35(4): 279-84

176:  Fossum JO, Fimland BO, Svare I I.
Anomalous ultrasonic attenuation in ammonium aluminum alum.
Phys Rev B Condens Matter.    impact factor:   3.008
1986;  33(2): 1434-1435

177:  Jarnicki AG, Tsuji T, Thomas WR.
Inhibition of mucosal and systemic T(h)2-type immune responses by intranasal peptides containing a dominant T cell epitope of the allergen Der p 1.
Int Immunol.    impact factor:   2.897
2001;  13(10): 1223-31

178:  Faquim-Mauro EL, Macedo MS.
Induction of IL-4-dependent, anaphylactic-type and IL-4-independent, non-anaphylactic-type IgG1 antibodies is modulated by adjuvants.
Int Immunol.    impact factor:   2.897
2000;  12(12): 1733-40

179:  De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C, Urbain J, Moser M.
The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells.
Int Immunol.    impact factor:   2.897
2000;  12(6): 807-15

180:  Kelso A, Groves P, Ramm L, Doyle AG.
Single-cell analysis by RT-PCR reveals differential expression of multiple type 1 and 2 cytokine genes among cells within polarized CD4+ T cell populations.
Int Immunol.    impact factor:   2.897
1999;  11(4): 617-21

181:  Sedlik C, Rojas M, Leclerc C.
Activation of B cells by 1 microm particulate lysozyme or peptides: a Th-dependent pathway requiring CD40-CD40 ligand interaction.
Int Immunol.    impact factor:   2.897
1998;  10(8): 1111-9

182:  Romieu R, Baratin M, Kayibanda M, Guillet JG, Viguier M.
IFN-gamma-secreting Th cells regulate both the frequency and avidity of epitope-specific CD8+ T lymphocytes induced by peptide immunization: an ex vivo analysis.
Int Immunol.    impact factor:   2.897
1998;  10(9): 1273-9

183:  St Clair EW, Cohen SB, Lee ML, Fleischmann RM, Lee SH, Moreland LW, Olsen NJ, Pratt PW, Yocum DE, Heck L, Winkelhake J, Holcenberg JS, Shulman MJ.
Treatment of rheumatoid arthritis with a DR4/1 peptide.
J Rheumatol.    impact factor:   2.879
2000;  27(8): 1855-63

184:  Migasena S, Suntharasamai P, Pitisuttithum P, Kitayaporn D, Wasi C, Huang W, Vanichseni S, Koompong C, Kaewkungwal J, Raktham S, Ippolito T, Hanson C, Gregory T, Heyward WL, Berman P, Francis D.
AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization.
AIDS Res Hum Retroviruses.    impact factor:   2.87
2000;  16(7): 655-63

185:  Aubertin AM, Le Grand R, Wang Y, Beyer C, Tao L, Neildez O, Barre-Sinoussi F, Hurtrel B, Moog C, Lehner T, Girard M.
Generation of CD8+ T cell-generated suppressor factor and beta-chemokines by targeted iliac lymph node immunization in rhesus monkeys challenged with SHIV-89.6P by the rectal route.
AIDS Res Hum Retroviruses.    impact factor:   2.87
2000;  16(4): 381-92

186:  Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB.
HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
AIDS Res Hum Retroviruses.    impact factor:   2.87
1999;  15(2): 115-32

187:  Cox JH, Garner RP, Redfield RR, Aronson NE, Davis C, Ruiz N, Birx DL.
Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine.
AIDS Res Hum Retroviruses.    impact factor:   2.87
1999;  15(9): 847-54

188:  Benson EM, Clarkson J, Law M, Marshall P, Kelleher AD, Smith DE, Patou G, Stewart GJ, Cooper DA, French RA.
Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals.
AIDS Res Hum Retroviruses.    impact factor:   2.87
1999;  15(2): 105-13

189:  McNicholl JM, Bond KB, Ruhadze ER, Olsen MR, Takayama K, Hunter RL.
Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
AIDS Res Hum Retroviruses.    impact factor:   2.87
1998;  14(16): 1457-71

190:  Francis DP, Gregory T, McElrath MJ, Belshe RB, Gorse GJ, Migasena S, Kitayaporn D, Pitisuttitham P, Matthews T, Schwartz DH, Berman PW.
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
AIDS Res Hum Retroviruses.    impact factor:   2.87
1998;  14 Suppl 3: S325-31

191:  Sauzet JP, Moog C, Krivine A, Martinon F, Bossus M, Gras-Masse H, Tartar A, Guillet JG, Gomard E.
Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivo.
AIDS Res Hum Retroviruses.    impact factor:   2.87
1998;  14(10): 901-9

192:  Zimmerman DH, Ulrich JT, Wright C, Lloyd JP, Winship MD, Sarin PS.
Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.
AIDS Res Hum Retroviruses.    impact factor:   2.87
1998;  14(9): 741-9

193:  Tsoukas CM, Raboud J, Bernard NF, Montaner JS, Gill MJ, Rachlis A, Fong IW, Schlech W, Djurdjev O, Freedman J, Thomas R, Lafreniere R, Wainberg MA, Cassol S, O'Shaughnessy M, Todd J, Volvovitz F, Smith GE.
Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency.
AIDS Res Hum Retroviruses.    impact factor:   2.87
1998;  14(6): 483-90

194:  Li F, Riddell MA, Seow HF, Takeda N, Miyamura T, Anderson DA.
Recombinant subunit ORF2.1 antigen and induction of antibody against immunodominant epitopes in the hepatitis E virus capsid protein.
J Med Virol.    impact factor:   2.867
2000;  60(4): 379-86

195:  Cha YH, Strauss HL.
Local structure and tunneling kinetics of ammonium aluminum alum by infrared hole-burning.
Inorg Chem.    impact factor:   2.843
2001;  40(6): 1176-82

196:  Lindqvist-Reis P, Munoz-Paez A, Diaz-Moreno S, Pattanaik S, Persson I, Sandstrom M.
The Structure of the Hydrated Gallium(III), Indium(III), and Chromium(III) Ions in Aqueous Solution. A Large Angle X-ray Scattering and EXAFS Study.
Inorg Chem.    impact factor:   2.843
1998;  37(26): 6675-6683

197:  Mandokhot A, Pal R, Nagpal S, Chauhan VS, Ahlawat S, Singh O.
Humoral hyporesponsiveness to a conjugate contraceptive vaccine and its bypass by diverse carriers using permissible adjuvant.
Clin Exp Immunol.    impact factor:   2.831
2000;  122(1): 101-8

198:  Poltl-Frank F, Zurbriggen R, Helg A, Stuart F, Robinson J, Gluck R, Pluschke G.
Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.
Clin Exp Immunol.    impact factor:   2.831
1999;  117(3): 496-503

199:  Vlase H, Weiss M, Graves PN, Davies TF.
Characterization of the murine immune response to the murine TSH receptor ectodomain: induction of hypothyroidism and TSH receptor antibodies.
Clin Exp Immunol.    impact factor:   2.831
1998;  113(1): 111-8

200:  Bhattachary-Chatterjee M, Nath Baral R, Chatterjee SK, Das R, Zeytin H, Chakraborty M, Foon KA.
Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.
Cancer Immunol Immunother.    impact factor:   2.82
2000;  49(3): 133-41

201:  Maruyama H, Zaloudik J, Li W, Sperlagh M, Koido T, Somasundaram R, Scheck S, Prewett M, Herlyn D.
Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.
Cancer Immunol Immunother.    impact factor:   2.82
2000;  49(3): 123-32

202:  Pietersz GA, Li W, Popovski V, Caruana JA, Apostolopoulos V, McKenzie IF.
Parameters for using mannan-MUC1 fusion protein to induce cellular immunity.
Cancer Immunol Immunother.    impact factor:   2.82
1998;  45(6): 321-6

203:  Bhattacharjee G, Misra UK, Gawdi G, Cianciolo G, Pizzo SV.
Inducible expression of the alpha2-macroglobulin signaling receptor in response to antigenic stimulation: a study of second messenger generation.
J Cell Biochem.    impact factor:   2.817
2001;  82(2): 260-70

204:  Kantak KM, Collins SL, Bond J, Fox BS.
Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010.
Psychopharmacology (Berl).    impact factor:   2.804
2001;  153(3): 334-40

205:  Von Garnier C, Astori M, Kettner A, Dufour N, Corradin G, Spertini F.
In vivo kinetics of the immunoglobulin E response to allergen: bystander effect of coimmunization and relationship with anaphylaxis.
Clin Exp Allergy.    impact factor:   2.702
2002;  32(3): 401-10

206:  Hussain I, Randolph D, Brody SL, Song SK, Hsu A, Kahn AM, Chaplin DD, Hamilos DL.
Induction, distribution and modulation of upper airway allergic inflammation in mice.
Clin Exp Allergy.    impact factor:   2.702
2001;  31(7): 1048-59

207:  Mellerup MT, Hahn GW, Poulsen LK, Malling H.
Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment.
Clin Exp Allergy.    impact factor:   2.702
2000;  30(10): 1423-9

208:  Rask C, Holmgren J, Fredriksson M, Lindblad M, Nordstrom I, Sun JB, Czerkinsky C.
Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice.
Clin Exp Allergy.    impact factor:   2.702
2000;  30(7): 1024-32

209:  Ramasamy R, Kanagaratnam R, Chandanie PD, Kulachelvy K, Ramasamy MS, Dharmasena PM.
Model multiple antigenic and homopolymeric peptides from non-repetitive sequences of malaria merozoite proteins elicit biologically irrelevant antibodies.
Biochim Biophys Acta.    impact factor:   2.59
1999;  1453(1): 115-25

210:  Gronlund H, Vrtala S, Wiedermann U, Dekan G, Kraft D, Valenta R, Van Hage-Hamsten M.
Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy.
Immunology.    impact factor:   2.575
2002;  107(4): 523-9

211:  Yang X, Fan Y, Wang S, Han X, Yang J, Bilenki L, Chen L.
Mycobacterial infection inhibits established allergic inflammatory responses via alteration of cytokine production and vascular cell adhesion molecule-1 expression.
Immunology.    impact factor:   2.575
2002;  105(3): 336-43

212:  Lehner T, Wang Y, Cranage M, Tao L, Mitchell E, Bravery C, Doyle C, Pratt K, Hall G, Dennis M, Villinger L, Bergmeier L.
Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates.
Immunology.    impact factor:   2.575
2000;  99(4): 569-77

213:  Toda M, Sato H, Takebe Y, Taniguchi Y, Saito S, Inouye S, Takemori T, Sakaguchi M.
Inhibition of immunoglobulin E response to Japanese cedar pollen allergen (Cry j 1) in mice by DNA immunization: different outcomes dependent on the plasmid DNA inoculation method.
Immunology.    impact factor:   2.575
2000;  99(2): 179-86

214:  Yang X, Wang S, Fan Y, Zhu L.
Systemic mycobacterial infection inhibits antigen-specific immunoglobulin E production, bronchial mucus production and eosinophilic inflammation induced by allergen.
Immunology.    impact factor:   2.575
1999;  98(3): 329-37

215:  Kang KW, Kim TS, Kim KM.
Interferon-gamma- and interleukin-4-targeted gene therapy for atopic allergic disease.
Immunology.    impact factor:   2.575
1999;  97(3): 462-5

216:  Brewer JM, Conacher M, Gaffney M, Douglas M, Bluethmann H, Alexander J.
Neither interleukin-6 nor signalling via tumour necrosis factor receptor-1 contribute to the adjuvant activity of Alum and Freund's adjuvant.
Immunology.    impact factor:   2.575
1998;  93(1): 41-8

217:  Dupont AL.
Study of the degradation of gelatin in paper upon aging using aqueous size-exclusion chromatography.
J Chromatogr A.    impact factor:   2.52
2002;  950(1-2): 113-24

218:  Del Pizzo JJ, Chew BH, Jacobs SC, Sklar GN.
Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen: long-term followup.
J Urol.    impact factor:   2.486
1998;  160(3 Pt 1): 731-3

219:  Jung T, Kamm W, Breitenbach A, Hungerer KD, Hundt E, Kissel T.
Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice.
Pharm Res.    impact factor:   2.475
2001;  18(3): 352-60

220:  Mukhopadhyay A, Bhatia PK, Majumdar SS.
Preliminary studies with recombinant chorionic gonadotropin beta-subunit produced in Escherichia coli for use as an antigen in a birth control vaccine.
Am J Reprod Immunol.    impact factor:   2.448
1998;  39(3): 172-82

221:  Saijo T, Kim JJ, Kuroda Y, Tanaka K.
The roles of threonine-136 and glutamate-137 of human medium chain acyl-CoA dehydrogenase in FAD binding and peptide folding using site-directed mutagenesis: creation of an FAD-dependent mutant, T136D.
Arch Biochem Biophys.    impact factor:   2.386
1998;  358(1): 49-57

222:  Sims JT, Luka-McCafferty NJ.
On-farm evaluationof aluminum sulfate (alum) as a poultry litter amendment: effects on litter properties.
J Environ Qual.    impact factor:   2.357
2002;  31(6): 2066-73

223:  Smith DR, Moore PA Jr, Griffis CL, Daniel TC, Edwards DR, Boothe DL.
Effects of alum and aluminum chloride on phosphorus runoff from swine manure.
J Environ Qual.    impact factor:   2.357
2001;  30(3): 992-8

224:  Campbell A, Yang EY, Tsai-Turton M, Bondy SC.
Pro-inflammatory effects of aluminum in human glioblastoma cells.
Brain Res.    impact factor:   2.302
2002;  933(1): 60-5

225:  Yang EY, Guo-Ross SX, Bondy SC.
The stabilization of ferrous iron by a toxic beta-amyloid fragment and by an aluminum salt.
Brain Res.    impact factor:   2.302
1999;  839(2): 221-6

226:  Bondy SC, Guo-Ross SX, Truong AT.
Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid.
Brain Res.    impact factor:   2.302
1998;  799(1): 91-6

227:  Machluf M, Apte RN, Regev O, Cohen S.
Enhancing the immunogenicity of liposomal hepatitis B surface antigen (HBsAg) by controlling its delivery from polymeric microspheres.
J Pharm Sci.    impact factor:   2.27
2000;  89(12): 1550-7

228:  Lutsiak CM, Sosnowski DL, Wishart DS, Kwon GS, Samuel J.
Use of a liposome antigen delivery system to alter immune responses in vivo.
J Pharm Sci.    impact factor:   2.27
1998;  87(11): 1428-32

229:  Singh M, McGee JP, Li XM, Koff W, Zamb T, Wang CY, O'Hagan DT.
Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine.
J Pharm Sci.    impact factor:   2.27
1997;  86(11): 1229-33

230:  Fuellen G, Wagele JW, Giegerich R.
Minimum conflict: a divide-and-conquer approach to phylogeny estimation.
Bioinformatics.    impact factor:   2.259
2001;  17(12): 1168-78

231:  Ebhardt MB, Shive CL, Guardia R, Gapin L, Boehm BO, Forsthuber TG.
Immunological adjuvants efficiently induce antigen-specific T cell responses in old mice: implications for vaccine adjuvant development in aged individuals.
Cell Immunol.    impact factor:   2.252
2002;  215(1): 87-97

232:  Schneider AM, Li F, Zhang X, Gordon JR.
Induction of pulmonary allergen-specific IgA responses or airway hyperresponsiveness in the absence of allergic lung disease following sensitization with limiting doses of ovalbumin-alum.
Cell Immunol.    impact factor:   2.252
2001;  212(2): 101-9

233:  Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, Reiter MJ, Smith MH, Tomai MA.
Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
Cell Immunol.    impact factor:   2.252
2000;  204(1): 64-74

234:  Guo-Ross S, Yang E, Bondy SC.
Elevation of cerebral proteases after systemic administration of aluminum.
Neurochem Int.    impact factor:   2.175
1998;  33(3): 277-82

235:  Dunsavage MB, O'Leary CJ, Baumgart TD, Solvason N, Howard M, Lafferty K, Deshpande S, Reich EP.
A conformationally-constrained MHC class II I-Ag7-derived peptide protects NOD mice from the development of diabetes.
J Autoimmun.    impact factor:   2.166
1999;  12(4): 233-42

236:  Peleg H, Bodine KK, Noble AC.
The influence of acid on astringency of alum and phenolic compounds.
Chem Senses.    impact factor:   2.163
1998;  23(3): 371-8

237:  Bondy SC, Truong A.
Potentiation of beta-folding of beta-amyloid peptide 25-35 by aluminum salts.
Neurosci Lett.    impact factor:   2.085
1999;  267(1): 25-8

238:  Diwan M, Tafaghodi M, Samuel J.
Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
J Control Release.    impact factor:   2.059
2002;  85(1-3): 247-62

239:  Johansen P, Corradin G, Merkle HP, Gander B.
Release of tetanus toxoid from adjuvants and PLGA microspheres: how experimental set-up and surface adsorption fool the pattern.
J Control Release.    impact factor:   2.059
1998;  56(1-3): 209-17

240:  Rodrigues MM, Soares MB, Vasconcelos JR.
Endogenous interleukin-4 downregulates the type 1 CD4 T cell-mediated immune response induced by intramuscular DNA immunization.
J Interferon Cytokine Res.    impact factor:   2.024
2002;  22(11): 1137-41

241:  Chen Y, Boros DL.
The Schistosoma mansoni egg-derived r38 peptide-induced Th1 response affects the synchronous pulmonary but not the asynchronous hepatic granuloma growth.
Parasite Immunol.    impact factor:   2.014
2001;  23(1): 43-50

242:  Pereira-Chioccola VL, Costa F, Ribeirao M, Soares IS, Arena F, Schenkman S, Rodrigues MM.
Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.
Parasite Immunol.    impact factor:   2.014
1999;  21(2): 103-10

243:  Suri PK, Goldberg M, Madikizela M, Petzke MM, Bungiro RD Jr, Davies SJ, Chakraborty B, Nguyen KB, McCray JW Jr, Knopf PM.
Evaluation of recombinant protein r140, a polypeptide segment of tegumental glycoprotein Sm25, as a defined antigen vaccine against Schistosoma mansoni.
Parasite Immunol.    impact factor:   2.014
1997;  19(11): 515-29

244:  Puumalainen T, Zeta-Capeding MR, Kayhty H, Lucero MG, Auranen K, Leroy O, Nohynek H.
Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants.
Pediatr Infect Dis J.    impact factor:   2.01
2002;  21(4): 309-14

245:  Sinha RK, Khuller GK.
The protective efficacy of a liposomal encapsulated 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra against tuberculosis in mice.
Immunol Cell Biol.    impact factor:   2.006
1997;  75(5): 461-6

246:  Migliore L, Cocchi L, Nesti C, Sabbioni E.
Micronuclei assay and FISH analysis in human lymphocytes treated with six metal salts.
Environ Mol Mutagen.    impact factor:   1.99
1999;  34(4): 279-84

247:  Lochner M, Wagner H, Classen M, Forster I.
Generation of neutralizing mouse anti-mouse IL-18 antibodies for inhibition of inflammatory responses in vivo.
J Immunol Methods.    impact factor:   1.95
2002;  259(1-2): 149-57

248:  Adel-Patient K, Creminon C, Bernard H, Clement G, Negroni L, Frobert Y, Grassi J, Wal JM, Chatel JM.
Evaluation of a high IgE-responder mouse model of allergy to bovine beta-lactoglobulin (BLG): development of sandwich immunoassays for total and allergen-specific IgE, IgG1 and IgG2a in BLG-sensitized mice.
J Immunol Methods.    impact factor:   1.95
2000;  235(1-2): 21-32

249:  Simmons M, Murphy GS, Kochel T, Raviprakash K, Hayes CG.
Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine.
Am J Trop Med Hyg.    impact factor:   1.932
2001;  65(5): 420-6

250:  Collins WE, Kaslow DC, Sullivan JS, Morris CL, Galland GG, Yang C, Saekhou AM, Xiao L, Lal AA.
Testing the efficacy of a recombinant merozoite surface protein (MSP-1(19) of Plasmodium vivax in Saimiri boliviensis monkeys.
Am J Trop Med Hyg.    impact factor:   1.932
1999;  60(3): 350-6

251:  Gorman SP, Levy JK, Hampton AL, Collante WR, Harris AL, Brown RG.
Evaluation of a porcine zona pellucida vaccine for the immunocontraception of domestic kittens (Felis catus).
Theriogenology.    impact factor:   1.923
2002;  58(1): 135-49

252:  Cho KS, Ryu HW, Lee EG, Chang YK.
Separation of Alcaligenes eutrophus cells containing Poly(3-hydroxybutyrate) from fermentation broth with pretreatment using Al- and Fe-based coagulants.
Biotechnol Prog.    impact factor:   1.897
2000;  16(2): 238-43

253:  Houri-Haddad Y, Soskoine WA, Shapira L.
Immunization to Porphyromonas gingivalis enhances the local pro-inflammatory response to subcutaneous bacterial challenge.
J Clin Periodontol.    impact factor:   1.873
2001;  28(5): 476-82

254:  Soares IS, Rodrigues MM.
Immunogenic properties of the Plasmodium vivax vaccine candidate MSP1(19) expressed as a secreted non-glycosylated polypeptide from Pichia pastoris.
Parasitology.    impact factor:   1.868
2002;  124(Pt 3): 237-46

255:  Mansour JM, McCrossan MV, Bickle QD, Mansour TE.
Schistosoma mansoni phosphofructokinase: immunolocalization in the tegument and immunogenicity.
Parasitology.    impact factor:   1.868
2000;  120 ( Pt 5): 501-11

256:  Chargelegue D, Vine ND, van Dolleweerd CJ, Drake PM, Ma JK.
A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice.
Transgenic Res.    impact factor:   1.849
2000;  9(3): 187-94

257:  Nakamura H, Rose PG, Blumer JL, Reed MD.
Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis.
J Clin Pharmacol.    impact factor:   1.827
2000;  40(3): 296-300

258:  Ito T, Inouye K, Fujimaki H, Tohyama C, Nohara K.
Mechanism of TCDD-induced suppression of antibody production: effect on T cell-derived cytokine production in the primary immune reaction of mice.
Toxicol Sci.    impact factor:   1.778
2002;  70(1): 46-54

259:  Fujimaki H, Nohara K, Kobayashi T, Suzuki K, Eguchi-Kasai K, Tsukumo S, Kijima M, Tohyama C.
Effect of a single oral dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin on immune function in male NC/Nga mice.
Toxicol Sci.    impact factor:   1.778
2002;  66(1): 117-24

260:  Bussiere JL, Hardy LM, Peterson M, Foss JA, Garman RH, Hoberman AM, Christian MS.
Lack of developmental neurotoxicity of MN rgp 120/HIV-1 administered subcutaneously to neonatal rats.
Toxicol Sci.    impact factor:   1.778
1999;  48(1): 90-9

261:  Li W, Ma KK, Sun W, Paudel HK.
Phosphorylation sensitizes microtubule-associated protein tau to Al(3+)-induced aggregation.
Neurochem Res.    impact factor:   1.755
1998;  23(12): 1467-76

262:  Gitis V, Adin A, Nasser A, Gun J, Lev O.
Fluorescent dye labeled bacteriophages--a new tracer for the investigation of viral transport in porous media: 2. Studies of deep-bed filtration.
Water Res.    impact factor:   1.748
2002;  36(17): 4235-42

263:  Zhao YQ, Bache DH.
Polymer impact on filter blinding during alum sludge filtration.
Water Res.    impact factor:   1.748
2002;  36(15): 3691-8

264:  Singer PC, Bilyk K.
Enhanced coagulation using a magnetic ion exchange resin.
Water Res.    impact factor:   1.748
2002;  36(16): 4009-22

265:  Bolto B, Dixon D, Eldridge R, King S.
Removal of THM precursors by coagulation or ion exchange.
Water Res.    impact factor:   1.748
2002;  36(20): 5066-73

266:  Al-Shamrani AA, James A, Xiao H.
Destabilisation of oil-water emulsions and separation by dissolved air flotation.
Water Res.    impact factor:   1.748
2002;  36(6): 1503-12

267:  Page DW, van Leeuwen JA, Spark KM, Drikas M, Withers N, Mulcahy DE.
Effect of alum treatment on the trihalomethane formation and bacterial regrowth potential of natural and synthetic waters.
Water Res.    impact factor:   1.748
2002;  36(19): 4884-92

268:  Ma J, Liu W.
Effectiveness and mechanism of potassium ferrate(VI) preoxidation for algae removal by coagulation.
Water Res.    impact factor:   1.748
2002;  36(4): 871-8

269:  Dai X, Hozalski RM.
Effect of NOM and biofilm on the removal of Cryptosporidium parvum oocysts in rapid filters.
Water Res.    impact factor:   1.748
2002;  36(14): 3523-32

270:  Henderson R, Carlson K, Gregory D.
The impact of ferrous ion reduction of chlorite ion on drinking water process performance.
Water Res.    impact factor:   1.748
2001;  35(18): 4464-73

271:  Kaggwa RC, Mulalelo CI, Denny P, Okurut TO.
The impact of alum discharges on a natural tropical wetland in Uganda.
Water Res.    impact factor:   1.748
2001;  35(3): 795-807

272:  Bolto B, Dixon D, Eldridge R, King S.
Cationic polymer and clay or metal oxide combinations for natural organic matter removal.
Water Res.    impact factor:   1.748
2001;  35(11): 2669-76

273:  Judd SJ, Hillis P.
Optimisation of combined coagulation and microfiltration for water treatment.
Water Res.    impact factor:   1.748
2001;  35(12): 2895-904

274:  Mekonen A, Kumar P, Kumar A.
Integrated biological and physiochemical treatment process for nitrate and fluoride removal.
Water Res.    impact factor:   1.748
2001;  35(13): 3127-36

275:  Chu W.
Dye removal from textile dye wastewater using recycled alum sludge.
Water Res.    impact factor:   1.748
2001;  35(13): 3147-52

276:  Bustamante HA, Shanker SR, Pashley RM, Karaman ME.
Interaction between Cryptosporidium oocysts and water treatment coagulants.
Water Res.    impact factor:   1.748
2001;  35(13): 3179-89

277:  Chen LC, Chian CY, Yen PS, Chu CP, Lee DJ.
High-speed sludge freezing.
Water Res.    impact factor:   1.748
2001;  35(14): 3502-7

278:  Ormeci B, Vesilind PA.
Effect of dissolved organic material and cations on freeze-thaw conditioning of activated and alum sludges.
Water Res.    impact factor:   1.748
2001;  35(18): 4299-306

279:  Sardinha LR, D'Imperio Lima MR, Alvarez JM.
Influence of the polyclonal activation induced by Plasmodium chabaudi on ongoing OVA-specific B- and T-cell responses.
Scand J Immunol.    impact factor:   1.74
2002;  56(4): 408-16

280:  Decroix N, Quan CP, Pamonsinlapatham P, Bouvet JP.
Mucosal immunity induced by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41.
Scand J Immunol.    impact factor:   1.74
2002;  56(1): 59-65

281:  Gardby E, Chen XJ, Lycke NY.
Impaired CD40-signalling in CD19-deficient mice selectively affects Th2-dependent isotype switching.
Scand J Immunol.    impact factor:   1.74
2001;  53(1): 13-23

282:  Lee YL, Fu CL, Ye YL, Chiang BL.
Administration of interleukin-12 prevents mite Der p 1 allergen-IgE antibody production and airway eosinophil infiltration in an animal model of airway inflammation.
Scand J Immunol.    impact factor:   1.74
1999;  49(3): 229-36

283:  Haddad D, Liljeqvist S, Stahl S, Hansson M, Perlmann P, Ahlborg N, Berzins K.
Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol.
Scand J Immunol.    impact factor:   1.74
1999;  49(5): 506-14

284:  Peng HJ, Chang ZN, Lin SY, Han SH, Chang CH.
Chemical denaturation of ovalbumin abrogates the induction of oral tolerance of mouse reaginic antibody responses.
Scand J Immunol.    impact factor:   1.74
1998;  47(5): 475-80

285:  Comoy EE, Capron A, Thyphronitis G.
Adjuvant is the major parameter influencing the isotype profiles generated during immunization with a protein antigen, the Schistosoma mansoni Sm28-GST.
Scand J Immunol.    impact factor:   1.74
1998;  47(5): 444-52

286:  Peng HJ, Chang ZN, Tsai LC, Su SN, Shen HD, Chang CH.
Heat denaturation of egg-white proteins abrogates the induction of oral tolerance of specific Th2 immune responses in mice.
Scand J Immunol.    impact factor:   1.74
1998;  48(5): 491-6

287:  Mattsson L, Lorentzen JC, Svelander L, Bucht A, Nyman U, Klareskog L, Larsson P.
Immunization with alum-collagen II complex suppresses the development of collagen-induced arthritis in rats by deviating the immune response.
Scand J Immunol.    impact factor:   1.74
1997;  46(6): 619-24

288:  Amara N, Ratsimba B, Wilhelm AM, Delmas H.
Crystallization of potash alum: effect of power ultrasound.
Ultrason Sonochem.    impact factor:   1.732
2001;  8(3): 265-70

289:  Stephanis CG, Hatiris JG, Mourmouras DE.
The process (mechanism) of erosion of soluble brittle materials caused by cavitation.
Ultrason Sonochem.    impact factor:   1.732
1997;  4(3): 269-71

290:  Rafi-Janajreh A, Tongren JE, Kensil C, Hackett C, Candal F, Lal A, Udhayakumar V.
Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice.
Exp Parasitol.    impact factor:   1.729
2002;  101(1): 3-12

291:  Gozar MM, Muratova O, Keister DB, Kensil CR, Price VL, Kaslow DC.
Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.
Exp Parasitol.    impact factor:   1.729
2001;  97(2): 61-9

292:  Carroll EE, Dubielzig RR, Schultz RD.
Cats differ from mink and ferrets in their response to commercial vaccines: a histologic comparison of early vaccine reactions.
Vet Pathol.    impact factor:   1.682
2002;  39(2): 216-27

293:  Lefcourt AM, Meisinger JJ.
Effect of adding alum or zeolite to dairy slurry on ammonia volatilization and chemical composition.
J Dairy Sci.    impact factor:   1.674
2001;  84(8): 1814-21

294:  Naito S, Taneichi M, Kato H, Tanaka Y, Ami Y, Suzaki Y, Mori M, Nakano Y, Yamamura H, Morokuma K, Ohkuma K, Miyake H, Kiniwa M, Komuro K, Uchida T.
Selective Inhibition of Systemic Anti-OVA IgE Production in Response to Oral Pre-Treatment with OVA-Liposome Conjugates.
Int Arch Allergy Immunol.    impact factor:   1.63
2002;  129(4): 314-9

295:  Ohta K, Yamashita N, Tajima M, Miyasaka T, Kawashima R, Nakano J, Arioka H, Ishii A, Horiuchi T, Miyamoto T.
In vivo effects of apoptosis in asthma examined by a murine model.
Int Arch Allergy Immunol.    impact factor:   1.63
2001;  124(1-3): 259-61

296:  Coenen TM, Ratajczak HV.
Equal allergenic potency of beta-lactam antibiotics produced by chemical or enzymatic manufacturing--mouse IgE test.
Int Arch Allergy Immunol.    impact factor:   1.63
2001;  126(2): 173-8

297:  Adel-Patient K, Creminon C, Boquet D, Wal JM, Chatel JM.
Genetic immunisation with bovine beta-lactoglobulin cDNA induces a preventive and persistent inhibition of specific anti-BLG IgE response in mice.
Int Arch Allergy Immunol.    impact factor:   1.63
2001;  126(1): 59-67

298:  Thomas MJ, MacAry PA, Noble A, Askenase PW, Kemeny DM.
T cytotoxic 1 and T cytotoxic 2 CD8 T cells both inhibit IgE responses.
Int Arch Allergy Immunol.    impact factor:   1.63
2001;  124(1-3): 187-9

299:  Wheeler AW, Marshall JS, Ulrich JT.
A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
Int Arch Allergy Immunol.    impact factor:   1.63
2001;  126(2): 135-9

300:  Yamashita N, Tajima M, Nakano J, Arioka H, Arai H, Miyasaka T, Kubota S, Kawashima R, Ohta K.
Induction of apoptosis in bronchial eosinophils: beneficial or harmful?
Int Arch Allergy Immunol.    impact factor:   1.63
2000;  122 Suppl 1: 40-3

301:  Nagafuchi S, Hachimura S, Totsuka M, Takahashi T, Goto M, Yajima T, Kuwata T, Habu S, Kaminogawa S.
Dietary nucleotides can up-regulate antigen-specific Th1 immune responses and suppress antigen-specific IgE responses in mice.
Int Arch Allergy Immunol.    impact factor:   1.63
2000;  122(1): 33-41

302:  Peng HJ, Chang ZN, Kuo SW, Lee CC, Tzau YY.
Resting B cells are not antigen-presenting cells in the induction of oral tolerance of specific Th2 immune responses in mice.
Int Arch Allergy Immunol.    impact factor:   1.63
2000;  122(3): 174-81

303:  Clarke AH, Thomas WR, Rolland JM, Dow C, O'Brien RM.
Murine allergic respiratory responses to the major house dust mite allergen Der p 1.
Int Arch Allergy Immunol.    impact factor:   1.63
1999;  120(2): 126-34

304:  Naito S, Horino A, Komiya T, Fukuda T, Takahashi M, Ami Y, Suzaki Y, Oka T, Okuma K, Morokuma M, Nakano Y, Mori M, Nishinohara S, Komuro K, Uchida T.
Induction of protection against tetanus toxin in mice by tetanus toxoid-liposome conjugate.
Int Arch Allergy Immunol.    impact factor:   1.63
1998;  116(3): 215-9

305:  Horie K, Chen D, Hoshi H.
Development of immune complex trapping: experimental study of lymphoid follicles and germinal centers newly induced by exogenous stimulants in mouse popliteal lymph nodes.
Histol Histopathol.    impact factor:   1.601
1999;  14(1): 11-21

306:  Filipov NM, Thompson FN, Hill NS, Dawe DL, Stuedemann JA, Price JC, Smith CK.
Vaccination against ergot alkaloids and the effect of endophyte-infected fescue seed-based diets on rabbits.
J Anim Sci.    impact factor:   1.569
1998;  76(9): 2456-63

307:  Carvalho C, Jancar S, Mariano M, Sirois P.
A rat model presenting eosinophilia in the airways, lung eosinophil activation, and pulmonary hyperreactivity.
Exp Lung Res.    impact factor:   1.563
1999;  25(4): 303-16

308:  Acosta CJ, Galindo CM, Schellenberg D, Aponte JJ, Kahigwa E, Urassa H, Schellenberg JR, Masanja H, Hayes R, Kitua AY, Lwilla F, Mshinda H, Menendez C, Tanner M, Alonso PL.
Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania.
Trop Med Int Health.    impact factor:   1.56
1999;  4(5): 368-76

309:  Swain C, Chainy GB.
Effects of aluminum sulphate and citric acid ingestion on lipid peroxidation and on activities of superoxide dismutase and catalase in cerebral hemisphere and liver of developing young chicks.
Mol Cell Biochem.    impact factor:   1.547
1998;  187(1-2): 163-72

310:  Deng X, Li H, Tang YW.
Cytokine expression in respiratory syncytial virus-infected mice as measured by quantitative reverse-transcriptase PCR.
J Virol Methods.    impact factor:   1.505
2003;  107(2): 141-6

311:  Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R.
Purification and characterization of hepatitis B virus surface antigen particles produced in Drosophila Schneider-2 cells.
J Virol Methods.    impact factor:   1.505
1999;  79(2): 205-17

312:  Morokata T, Ishikawa J, Yamada T.
Antigen dose defines T helper 1 and T helper 2 responses in the lungs of C57BL/6 and BALB/c mice independently of splenic responses.
Immunol Lett.    impact factor:   1.494
2000;  72(2): 119-26

313:  Nezlin R, Dayan M, Zinger H, Mozes E.
DNA levels in immune complexes circulating in mice with induced systemic lupus erythematosus.
Immunol Lett.    impact factor:   1.494
1999;  67(2): 85-90

314:  Morokata T, Ishikawa J, Yamada T.
Differential susceptibility of C57BL/6 and DBA/2 mice to ovalbumin-induced pulmonary eosinophilia regulated by Th1/Th2-type cytokines.
Immunol Lett.    impact factor:   1.494
1999;  70(2): 127-34

315:  Chu CP, Lee DJ, Huang C.
The Role of Ionic Surfactants in Compression Dewatering of Alum Sludge.
J Colloid Interface Sci.    impact factor:   1.494
1998;  206(1): 181-188

316:  Sujana MG, Thakur RS, Rao SB.
Removal of Fluoride from Aqueous Solution by Using Alum Sludge.
J Colloid Interface Sci.    impact factor:   1.494
1998;  206(1): 94-101

317:  Hotez PJ, Ashcom J, Bin Z, Bethony J, Williamson A, Hawdon JM, Jianjun F, Dobardzic A, Rizo I, Bolden J, Jin Q, Yan W, Dobardzic R, Chung-Debose S, Crowell M, Datu B, Delaney A, Dragonovski D, Jiang Y, Yueyuan L, Ghosh K, Loukas A, Brandt W, Russell PK, Zook BC.
Effect of vaccinations with recombinant fusion proteins on Ancylostoma caninum habitat selection in the canine intestine.
J Parasitol.    impact factor:   1.485
2002;  88(4): 684-90

318:  Perry CC, Shafran KL.
The systematic study of aluminium speciation in medium concentrated aqueous solutions.
J Inorg Biochem.    impact factor:   1.463
2001;  87(1-2): 115-24

319:  Tanaka H, Masuda T, Tokuoka S, Takahashi Y, Komai M, Nagao K, Nagai H.
Time course study on the development of allergen-induced airway remodeling in mice: the effect of allergen avoidance on established airway remodeling.
Inflamm Res.    impact factor:   1.441
2002;  51(6): 307-16

320:  Narita SI, Asakura K, Shiraski H, Isobe M, Ogasawara H, Saito H, Kataura A.
Effects of cyclosporin A and glucocorticosteroids on antigen-induced hypersensitivity to histamine in a guinea pig model of allergic rhinitis.
Inflamm Res.    impact factor:   1.441
1998;  47(2): 62-6

321:  Watanabe C, Hase K, Oku T, Koizumi F, Kadota S, Nagai H, Namba T, Saiki I.
Effect of spikelets of Miscanthus sinensis on IgE-mediated biphasic cutaneous reaction in mice.
Planta Med.    impact factor:   1.438
1998;  64(1): 12-7

322:  Capdevielle MC, Hart LE, Goff J, Scanes CG.
Aluminum and acid effects on calcium and phosphorus metabolism in young growing chickens (Gallus gallus domesticus) and mallard ducks (Anas platyrhynchos).
Arch Environ Contam Toxicol.    impact factor:   1.437
1998;  35(1): 82-8

323:  Hariharan K, Braslawsky G, Barnett RS, Berquist LG, Huynh T, Hanna N, Black A.
Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX.
Int J Oncol.    impact factor:   1.381
1998;  12(6): 1229-35

324:  Hancock GE, Heers KM, Smith JD.
QS-21 synergizes with recombinant interleukin-12 to create a potent adjuvant formulation for the fusion protein of respiratory syncytial virus.
Viral Immunol.    impact factor:   1.28
2000;  13(4): 503-9

325:  Qu D, Yuan ZH, He LF, Yang L, Li GD, Wen YM.
Effect of plasmid DNA on immunogenicity of HBsAg-anti-HBs complex.
Viral Immunol.    impact factor:   1.28
1998;  11(2): 65-72

326:  Blain JF, Sirois P.
Involvement of LTD(4)in allergic pulmonary inflammation in mice: modulation by cysLT(1)antagonist MK-571.
Prostaglandins Leukot Essent Fatty Acids.    impact factor:   1.226
2000;  62(6): 361-8

327:  Mohammed FI, Shafagoj YA.
Antiaggregation effect of alum on human platelets.
Int J Clin Pharmacol Ther.    impact factor:   1.222
2001;  39(7): 322-4

328:  Phelps KR, Naylor K, Brien TP, Wilbur H, Haqqie SS.
Encephalopathy after bladder irrigation with alum: case report and literature review.
Am J Med Sci.    impact factor:   1.217
1999;  318(3): 181-5

329:  Peters BS, Cheingsong-Popov R, Callow D, Foxall R, Patou G, Hodgkin K, Weber JN.
A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
J Infect.    impact factor:   1.188
1997;  35(3): 231-5

330:  Karanis P, Kimura A.
Evaluation of three flocculation methods for the purification of Cryptosporidium parvum oocysts from water samples.
Lett Appl Microbiol.    impact factor:   1.157
2002;  34(6): 444-9

331:  Wagner M, Brumelis D, Gehr R.
Disinfection of wastewater by hydrogen peroxide or peracetic acid: development of procedures for measurement of residual disinfectant and application to a physicochemically treated municipal effluent.
Water Environ Res.    impact factor:   1.146
2002;  74(1): 33-50

332:  Mantha R, Biswas N, Taylor KE, Bewtra JK.
Removal of nitroaromatics from synthetic wastewater using two-step zero-valent iron reduction and peroxidase-catalyzed oxidative polymerization.
Water Environ Res.    impact factor:   1.146
2002;  74(3): 280-7

333:  Ibrahim MS, Ali HI, Taylor KE, Biswas N, Bewtra JK.
Enzyme-catalyzed removal of phenol from refinery wastewater: feasibility studies.
Water Environ Res.    impact factor:   1.146
2001;  73(2): 165-72

334:  Nishida R, Inoue R, Takimoto Y, Kita T.
A sclerosant with astringent properties developed in China for oesophageal varices: comparison with ethanolamine oleate and polidocanol.
J Gastroenterol Hepatol.    impact factor:   1.116
1999;  14(5): 481-8

335:  Line JE.
Campylobacter and Salmonella populations associated with chickens raised on acidified litter.
Poult Sci.    impact factor:   1.107
2002;  81(10): 1473-7

336:  Moore PA Jr, Daniel TC, Edwards DR.
Reducing phosphorus runoff and improving poultry production with alum.
Poult Sci.    impact factor:   1.107
1999;  78(5): 692-8

337:  Burgess RP, Carey JB, Shafer DJ.
The impact of pH on nitrogen retention in laboratory analysis of broiler litter.
Poult Sci.    impact factor:   1.107
1998;  77(11): 1620-2

338:  Shu Q, Hillard MA, Bindon BM, Duan E, Xu Y, Bird SH, Rowe JB, Oddy VH, Gill HS.
Effects of various adjuvants on efficacy of a vaccine against Streptococcus bovis and Lactobacillus spp in cattle.
Am J Vet Res.    impact factor:   1.103
2000;  61(7): 839-43

339:  Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R.
Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins.
Clin Chem Lab Med.    impact factor:   1.084
1999;  37(3): 199-204

340:  Auci DL, Kleiner GI, Chice SM, Athanassiades TJ, Dukor P, Durkin HG.
Control of IgE responses. V. Oral administration of a synthetic derivative of the inner bacterial cell wall (SDZ 280.636) to sensitized mice induces isotype specific suppression of peak hapten specific IgE antibody forming cell responses, serum IgE levels and immediate hypersensitivity responses.
Immunol Invest.    impact factor:   1.084
1998;  27(1-2): 105-20

341:  Van Hullebusch E, Deluchat V, Chazal PM, Baudu M.
Environmental impact of two successive chemical treatments in a small shallow eutrophied lake: Part I. Case of aluminium sulphate.
Environ Pollut.    impact factor:   1.078
2002;  120(3): 617-26

342:  Van Hullebusch E, Deluchat V, Chazal PM, Baudu M.
Environmental impact of two successive chemical treatments in a small shallow eutrophied lake: Part II. Case of copper sulfate.
Environ Pollut.    impact factor:   1.078
2002;  120(3): 627-34

343:  Cecen F, Gursoy G.
Characterization of landfill leachates and studies on heavy metal removal.
J Environ Monit.    impact factor:   1.068
2000;  2(5): 436-42

344:  Hamada K, Goldsmith CA, Kobzik L.
Increased airway hyperresponsiveness and inflammation in a juvenile mouse model of asthma exposed to air-pollutant aerosol.
J Toxicol Environ Health A.    impact factor:   1.009
1999;  58(3): 129-43

345:  Kumar P, Biswas S, Rao DN.
Potentiation of immune response against the RESA peptides of Plasmodium falciparum by incorporating a universal T-cell epitope (CS.T3) and an immunomodulator (polytuftsin), and delivery through liposomes.
Microbiol Immunol.    impact factor:   1.004
1999;  43(6): 567-76

346:  Raghuvanshi RJ, Mistra A, Talwar GP, Levy RJ, Labhasetwar V.
Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid.
J Microencapsul.    impact factor:   .991
2001;  18(6): 723-32

347:  Desai MP, Hilfinger JM, Amidon GL, Levy RJ, Labhasetwar V.
Immune response with biodegradable nanospheres and alum: studies in rabbits using staphylococcal enterotoxin B-toxoid.
J Microencapsul.    impact factor:   .991
2000;  17(2): 215-25

348:  Huang HJ, Matsumoto M.
Immunity against Escherichia coli infection in chickens assessed by viable bacterial counts in internal organs.
Avian Dis.    impact factor:   .984
1999;  43(3): 469-75

349:  Raghuvanshi RS, Katare YK, Lalwani K, Ali MM, Singh O, Panda AK.
Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants.
Int J Pharm.    impact factor:   .952
2002;  245(1-2): 109-21

350:  Cui Z, Mumper RJ.
Coating of cationized protein on engineered nanoparticles results in enhanced immune responses.
Int J Pharm.    impact factor:   .952
2002;  238(1-2): 229-39

351:  Venkatesan N, Vyas SP.
Polysaccharide coated liposomes for oral immunization--development and characterization.
Int J Pharm.    impact factor:   .952
2000;  203(1-2): 169-77

352:  Sanchez A, Villamayor B, Guo Y, McIver J, Alonso MJ.
Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres.
Int J Pharm.    impact factor:   .952
1999;  185(2): 255-66

353:  Cunat L, Lanhers MC, Joyeux M, Burnel D.
Bioavailability and intestinal absorption of aluminum in rats: effects of aluminum compounds and some dietary constituents.
Biol Trace Elem Res.    impact factor:   .951
2000;  76(1): 31-55

354:  Inanc B, Calli B, Alp K, Ciner F, Mertoglu B, Ozturk I.
Toxicity assessment on combined biological treatment of pharmaceutical industry effluents.
Water Sci Technol.    impact factor:   .895
2002;  45(12): 135-42

355:  Ramirez Zamora RM, Orta de Velasquez MT, Duran Moreno A, Malpica de la Torre J.
Characterisation and conditioning of Fenton sludges issued from wastewater treatment.
Water Sci Technol.    impact factor:   .895
2002;  46(10): 43-9

356:  Zhao YQ, Papavasilopoulos EN, Bache DH, Mackinnon PA.
Polymer conditioning of alum sludge and discrepancies between estimates of the optimum dosage.
Water Sci Technol.    impact factor:   .895
2002;  46(10): 115-21

357:  Galil NI, Wolf D.
Removal of hydrocarbons from petrochemical wastewater by dissolved air flotation.
Water Sci Technol.    impact factor:   .895
2001;  43(8): 107-13

358:  Raper WG, Green JM.
Simple process for nutrient removal from food processing effluents.
Water Sci Technol.    impact factor:   .895
2001;  43(3): 123-30

359:  Kitis M, Karanfil T, Kilduff JE, Wigton A.
The reactivity of natural organic matter to disinfection by-products formation and its relation to specific ultraviolet absorbance.
Water Sci Technol.    impact factor:   .895
2001;  43(2): 9-16

360:  Wu CC, Wu JJ.
Effect of charge neutralization on the dewatering performance of alum sludge by polymer conditioning.
Water Sci Technol.    impact factor:   .895
2001;  44(10): 315-9

361:  Lee DY, Jing SR, Lin YF.
Using seafood waste as sludge conditioners.
Water Sci Technol.    impact factor:   .895
2001;  44(10): 301-7

362:  Papavasilopoulos EN, Bache DH.
Parallel studies on dewatering and conditioning of an alum sludge and an aluminium hydroxide suspension.
Water Sci Technol.    impact factor:   .895
2001;  44(10): 293-9

363:  Gregory J, Dupon V.
Properties of flocs produced by water treatment coagulants.
Water Sci Technol.    impact factor:   .895
2001;  44(10): 231-6

364:  Lee JC, Kim JS, Kang IJ, Cho MH, Park PK, Lee CH.
Potential and limitations of alum or zeolite addition to improve the performance of a submerged membrane bioreactor.
Water Sci Technol.    impact factor:   .895
2001;  43(11): 59-66

365:  Liu JC, Lien CS.
Pretreatment of bakery wastewater by coagulation-flocculation and dissolved air flotation.
Water Sci Technol.    impact factor:   .895
2001;  43(8): 131-7

366:  Han M, Kim W, Dockko S.
Collision efficiency factor of bubble and particle (alpha bp) in DAF: theory and experimental verification.
Water Sci Technol.    impact factor:   .895
2001;  43(8): 139-44

367:  Pinto Filho AC, Brandao CC.
Evaluation of flocculation and dissolved air flotation as an advanced wastewater treatment.
Water Sci Technol.    impact factor:   .895
2001;  43(8): 83-90

368:  Ng WJ, Ong SL, Hu JY.
The effects of water reclamation technologies on biological stability of industrial water.
Water Sci Technol.    impact factor:   .895
2001;  43(10): 327-34

369:  Yedla S, Mitra A, Bandyopadhyay M.
Purification of pulp and paper mill effluent using Eichornia crassipes.
Environ Technol.    impact factor:   .853
2002;  23(4): 453-65

370:  Basibuyuk M, Yilmaz T, Kayranli B, Yuceer A, Forster CF.
The use of waterworks sludge for the treatment of dye wastes.
Environ Technol.    impact factor:   .853
2002;  23(3): 345-51

371:  Choi JH, Shin WS, Lee SH, Joo DJ, Lee JD, Choi SJ.
Application of synthetic poly(DADM) flocculants for dye wastewater treatment.
Environ Technol.    impact factor:   .853
2001;  22(9): 1025-33

372:  Williford CW Jr, Bricka RM, Foster CC.
Reduction of suspended solids following hydroclassification of metal-contaminated soils.
J Hazard Mater.    impact factor:   .849
2002;  92(1): 63-75

373:  Dai Y, But PP, Chan YP, Matsuda H, Kubo M.
Antipruritic and antiinflammatory effects of aqueous extract from Si-Wu-Tang.
Biol Pharm Bull.    impact factor:   .844
2002;  25(9): 1175-8

374:  Suzuki T, Takano I, Nagai F, Fujitani T, Ushiyama K, Okubo T, Seto T, Ikeda S, Kano I.
Suppressive effects of Hochu-ekki-to, a traditional Chinese medicine, on IgE production and histamine release in mice immunized with ovalbumin.
Biol Pharm Bull.    impact factor:   .844
1999;  22(11): 1180-4

375:  Shu Q, Bir SH, Gill HS, Duan E, Xu Y, Hiliard, Rowe JB.
Antibody response in sheep following immunization with Streptococcus bovis in different adjuvants.
Vet Res Commun.    impact factor:   .817
2001;  25(1): 43-54

376:  Yamamoto H, Satoh T, Kiyohara T, Totsuka A, Moritsugu Y.
Quantitation of group-specific a antigen in hepatitis B vaccines by anti-HBs/a monoclonal antibody.
Biologicals.    impact factor:   .777
1997;  25(4): 373-80

377:  Farina M, Lara FS, Brandao R, Jacques R, Rocha JB.
Effects of aluminum sulfate on erythropoiesis in rats.
Toxicol Lett.    impact factor:   .773
2002;  132(2): 131-9

378:  Pimentel Vieira VL, Rocha JB, Schetinger MR, Morsch VM, Rodrigues SR, Tuerlinckz SM, Bohrer D, do Nascimento PC.
Effect of aluminum on delta-aminolevulinic acid dehydratase from mouse blood.
Toxicol Lett.    impact factor:   .773
2000;  117(1-2): 45-52

379:  Jokstad A.
Clinical trial of gingival retraction cords.
J Prosthet Dent.    impact factor:   .767
1999;  81(3): 258-61

380:  Hwang WJ, Park EJ, Jang CH, Han SW, Oh GJ, Kim NS, Kim HM.
Inhibitory effect of immunoglobulin E production by jin-deuk-chal (Siegesbeckia orientalis).
Immunopharmacol Immunotoxicol.    impact factor:   .761
2001;  23(4): 555-63

381:  Kaneko M, Kawakita T, Nomoto K.
Inhibition of eosinophil infiltration into the mouse peritoneal cavity by a traditional Chinese medicine, Bu-zhong-yi-qi-tang (Japanese name: Hochu-ekki-to).
Immunopharmacol Immunotoxicol.    impact factor:   .761
1999;  21(1): 125-40

382:  Osterborg A, Henriksson L, Mellstedt H.
Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
Acta Oncol.    impact factor:   .747
2000;  39(7): 797-800

383:  Bajaj AK, Gupta SC, Pandey RK, Misra K, Rastogi S, Chatterji AK.
Aluminium contact sensitivity.
Contact Dermatitis.    impact factor:   .741
1997;  37(6): 307-8

384:  Budantsev AY, Rudneva OA.
A simple method to determine hematoxylin ripening.
Biotech Histochem.    impact factor:   .714
1999;  74(4): 181-4

385:  Silva SS, Ramos RM, Rodrigues DC, Mancilha IM.
Downstream processing for xylitol recovery from fermented sugar cane bagasse hydrolysate using aluminium polychloride.
Z Naturforsch [C].    impact factor:   .709
2000;  55(1-2): 10-5

386:  Lin YF, Jing SR, Lee DY.
Recycling of wood chips and wheat dregs for sludge processing.
Bioresour Technol.    impact factor:   .7
2001;  76(2): 161-3

387:  Tariq M, Morais C, Sujata B, Sobki S, al Sulaiman M, al Khader A.
Aluminum exacerbates cyclosporin induced nephrotoxicity in rats.
Ren Fail.    impact factor:   .617
1999;  21(1): 35-48

388:  Murabayashi H, Hondo E, Kitamura N, Furuoka H, Taguchi K, Nambo Y, Yamada J.
Morphological study on pigmented cells in the horse testis.
J Vet Med Sci.    impact factor:   .567
1999;  61(10): 1183-6

389:  Kopac I, Batista U, Cvetko E, Marion L.
Viability of fibroblasts in cell culture after treatment with different chemical retraction agents.
J Oral Rehabil.    impact factor:   .56
2002;  29(1): 98-104

390:  Del Rocio Nieto-Martinez M, Maupome G, Barcelo-Santana F.
Effects of diameter, chemical impregnation and hydration on the tensile strength of gingival retraction cords.
J Oral Rehabil.    impact factor:   .56
2001;  28(12): 1094-100

391:  Schetinger MR, Bonan CD, Morsch VM, Bohrer D, Valentim LM, Rodrigues SR.
Effects of aluminum sulfate on delta-aminolevulinate dehydratase from kidney, brain, and liver of adult mice.
Braz J Med Biol Res.    impact factor:   .517
1999;  32(6): 761-6

392:  Udom EJ, Umoh MS, Udosen EO.
Recto-vaginal fistula following coitus: an aftermath of vaginal douching with aluminium potassium sulphate dodecahydrate (potassium alum).
Int J Gynaecol Obstet.    impact factor:   .49
1999;  66(3): 299-300

393:  Gallego H, Lewis EJ, Crutchfield CE 3rd.
Crystal deodorant dermatitis: irritant dermatitis to alum-containing deodorant.
Cutis.    impact factor:   .452
1999;  64(1): 65-6

394:  Weissbach L.
[Palliation of urothelial carcinoma of the bladder]
Urologe A.    impact factor:   .444
2001;  40(6): 475-9

395:  Howd RA.
Can we protect everybody from drinking water contaminants?
Int J Toxicol.    impact factor:   .413
2002;  21(5): 389-95

396:  Levic L, Gyura J.
Influence of aluminium sulphate concentration on the change of electrokinetic potential of macromolecular compounds in molasses.
Nahrung.    impact factor:   .395
2000;  44(4): 288-9

397:  Brennan FR, Gilleland LB, Staczek J, Bendig MM, Hamilton WD, Gilleland HE Jr.
A chimaeric plant virus vaccine protects mice against a bacterial infection.
Microbiology.    impact factor:   .338
1999;  145 ( Pt 8): 2061-7

398:  Puget FP, Halasz MR, Massarani G, Alves TL.
Influence of the flocculating agent in sedimentation and performance of a non flocculent strain of Zymomonas mobilis in the ethanol production process.
Bioseparation.    impact factor:   .298
2000;  9(3): 119-24

399:  Arora N, Gangal SV.
Liposome entrapped allergen reduces plasma histamine in sensitized mice.
Asian Pac J Allergy Immunol.    impact factor:   .186
1998;  16(2-3): 87-91

400:  Li G, Xie L, Zhou G, Fu H, Zhou J, Sun Q.
A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients.
Chin Med J (Engl).    impact factor:   .107
2002;  115(4): 567-70

401:  Chen D, Colditz IG, Glenn GM, Tsonis CG.
Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep.
Vet Immunol Immunopathol.    impact factor:   0
2002;  86(3-4): 177-82

402:  Ramirez DM, Leppla SH, Schneerson R, Shiloach J.
Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis.
J Ind Microbiol Biotechnol.    impact factor:   0
2002;  28(4): 232-8

403:  Zhao YQ, Bache DH.
Integrated effects of applied pressure, time, and polymer doses on alum sludge dewatering behaviour.
Waste Manag.    impact factor:   0
2002;  22(7): 813-9

404:  Birmingham N, Thanesvorakul S, Gangur V.
Relative immunogenicity of commonly allergenic foods versus rarely allergenic and nonallergenic foods in mice.
J Food Prot.    impact factor:   0
2002;  65(12): 1988-91

405:  Wang Y, Guo J, Tang H.
Pilot testing of dissolved air flotation (DAF) in a highly effective coagulation-flocculation integrated (FRD) system.
J Environ Sci Health Part A Tox Hazard Subst Environ Eng.    impact factor:   0
2002;  37(1): 95-111

406:  Qu JH, Lei PJ, Liu HJ.
Double catholyte electrochemical approach for preparing ferrate-aluminum: a compound oxidant-coagulant for water purification.
J Environ Sci (China).    impact factor:   0
2002;  14(1): 49-53

407:  Sadakane K, Takano H, Ichinose T, Yanagisawa R, Shibamoto T.
Formaldehyde enhances mite allergen-induced eosinophilic inflammation in the murine airway.
J Environ Pathol Toxicol Oncol.    impact factor:   0
2002;  21(3): 267-76

408:  Bhatia S, Mukhopadhyay S, Jarman E, Hall G, George A, Basu SK, Rath S, Lamb JR, Bal V.
Scavenger receptor-specific allergen delivery elicits IFN-gamma-dominated immunity and directs established TH2-dominated responses to a nonallergic phenotype.
J Allergy Clin Immunol.    impact factor:   0
2002;  109(2): 321-8

409:  Teuber SS, Del Val G, Morigasaki S, Jung HR, Eisele PH, Frick OL, Buchanan BB.
The atopic dog as a model of peanut and tree nut food allergy.
J Allergy Clin Immunol.    impact factor:   0
2002;  110(6): 921-7

410:  Wang X, Jin P.
[Dynamic properties of Al-humic flocs]
Huan Jing Ke Xue.    impact factor:   0
2002;  23(4): 71-5

411:  Nishino K, Fukushima A, Okamoto S, Ohashi Y, Fukata K, Ozaki A, Ueno H.
Suppression of experimental immune-mediated blepharoconjunctivitis in Brown Norway rats by topical application of FK506.
Graefes Arch Clin Exp Ophthalmol.    impact factor:   0
2002;  240(2): 137-43

412:  McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.
Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
FEMS Immunol Med Microbiol.    impact factor:   0
2002;  32(3): 179-85

413:  Kawai Y, Watanabe M, Matsuura M, Nishijima M, Kawahara K.
The partially degraded lipopolysaccharide of Burkholderia cepacia and ornithine-containing lipids derived from some Gram-negative bacteria are useful complex lipid adjuvants.
FEMS Immunol Med Microbiol.    impact factor:   0
2002;  34(3): 173-9

414:  He Q, Mitchell A, Morcol T, Bell SJ.
Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2.
Clin Diagn Lab Immunol.    impact factor:   0
2002;  9(5): 1021-4

415:  Panilaitis B, Johri A, Blank W, Kaplan D, Fuhrman J.
Adjuvant activity of emulsan, a secreted lipopolysaccharide from acinetobacter calcoaceticus.
Clin Diagn Lab Immunol.    impact factor:   0
2002;  9(6): 1240-7

416:  Kitagaki K, Jain VV, Businga TR, Hussain I, Kline JN.
Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses.
Clin Diagn Lab Immunol.    impact factor:   0
2002;  9(6): 1260-9

417:  Owen PJ, Miles DP, Draper GJ, Vincent TJ.
Retrospective study of mortality after a water pollution incident at Lowermoor in north Cornwall.
BMJ.    impact factor:   0
2002;  324(7347): 1189

418:  Hu H, Liao L, Wang X.
[Effect of low molecular weight organic acids on inorganic phosphorus transformation in red soil and its acidity]
Ying Yong Sheng Tai Xue Bao.    impact factor:   0
2002;  13(7): 867-70

419:  Tong YP, Zhan MY, Lu J, Bai Y, Bi SL, Zeng Y.
[Immunogenicity of recombinant HEV ORF2 protein expressed in pichia pastoris]
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi.    impact factor:   0
2002;  16(1): 23-6

420:  Matsumoto K, Hayakawa H, Ide K, Suda T, Chida K, Hashimoto H, Sato A, Nakamura H.
Effects of suplatast tosilate on cytokine profile of bronchoalveolar cells in allergic inflammation of the lung.
Respirology.    impact factor:   0
2002;  7(3): 201-7

421:  Cross ML, Mortensen RR, Kudsk J, Gill HS.
Dietary intake of Lactobacillus rhamnosus HNOO1 enhances production of both Th1 and Th2 cytokines in antigen-primed mice.
Med Microbiol Immunol (Berl).    impact factor:   0
2002;  191(1): 49-53

422:  Bergmeier LA, Wang Y, Lehner T.
The role of immunity in protection from mucosal SIV infection in macaques.
Oral Dis.    impact factor:   0
2002;  8 Suppl 2: 63-8

423:  Adel-Patient K, Creminon Ch, Boquet D, Wal JM, Chatel JM.
[Prevention of an IgE response to bovine beta-lactoglobulin by gene immunization in mice]
Allerg Immunol (Paris).    impact factor:   0
2002;  34(3): 77-81

424:  Nawghare P, Rao NN, Bejankiwar R, Szyprkowicz L, Kaul SN.
Treatment of phosphoric acid plant wastewater using Fenton's reagent and coagulants.
J Environ Sci Health Part A Tox Hazard Subst Environ Eng.    impact factor:   0
2001;  36(10): 2011-26

425:  Pinotti A, Zaritzky N.
Effect of aluminum sulfate and cationic polyelectrolytes on the destabilization of emulsified wastes.
Waste Manag.    impact factor:   0
2001;  21(6): 535-42

426:  Yadav D, Khuller GK.
Evaluation of immune responses directed against 30kDa secretory protein of Mycobacterium tuberculosis H37Ra complexed in different adjuvants.
Indian J Exp Biol.    impact factor:   0
2001;  39(12): 1227-34

427:  Lin YF, Jing SR, Lee DY.
Enhancing the dewaterability and amenability of sludge for subsequent stabilization processes by using organic waste solids as conditioners.
J Environ Sci Health Part A Tox Hazard Subst Environ Eng.    impact factor:   0
2001;  36(2): 191-202

428:  Thomas BE, Manocha M, Haq W, Adak T, Pillai CR, Rao DN.
Modulation of the humoral response to repeat and non-repeat sequences of the circumsporozoite protein of Plasmodium vivax using novel adjuvant and delivery systems.
Ann Trop Med Parasitol.    impact factor:   0
2001;  95(5): 451-72

429:  Birebent B, Koido T, Mitchell E, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai E, Herlyn D.
Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients.
J Cancer Res Clin Oncol.    impact factor:   0
2001;  127 Suppl 2: R27-33

430:  Weeratna RD, Brazolot Millan CL, McCluskie MJ, Siegrist CA, Davis HL.
Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies.
FEMS Immunol Med Microbiol.    impact factor:   0
2001;  30(3): 241-7

431:  Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL.
CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.
FEMS Immunol Med Microbiol.    impact factor:   0
2001;  32(1): 65-71

432:  Kuribayashi K, Takenaka T.
[Effects of adjuvants on the function of antigen presenting cells in the production of IgE in mice]
Rinsho Byori.    impact factor:   0
2001;  49(4): 365-9

433:  Kumar M, Behera AK, Hu J, Lockey RF, Mohapatra SS.
IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy.
J Allergy Clin Immunol.    impact factor:   0
2001;  108(3): 402-8

434:  MacLean DS, Robertson JD, Jay M.
Monitoring the retention of a protein antigen in complete Freund's adjuvant, alum, and pluronic F-127 gel formulations by X-ray fluorescence.
Pharm Dev Technol.    impact factor:   0
2001;  6(2): 241-6

435:  Kopac I, Cvetko E, Pavlica Z, Marion L.
Gingival tissue inflammatory response following treatment with chemical retraction agents in Beagle dogs.
Pflugers Arch.    impact factor:   0
2001;  442(6 Suppl 1): R145-6

436:  Gao BY, Yue QY, Yu H, Wang Y.
Distribution of aluminum species and the characteristics of structure of poly-aluminum-chloride-sulfate(PACS).
J Environ Sci (China).    impact factor:   0
2001;  13(1): 108-14

437:  McAnally JL, Xu L, Villain M, Blalock JE.
The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis.
Exp Biol Med (Maywood).    impact factor:   0
2001;  226(4): 307-11

438:  Tian H, Xiao Y, Zhu M, Chen YH.
HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies.
Int Immunopharmacol.    impact factor:   0
2001;  1(4): 763-8

439:  Hao YM, Shen HX.
Application of aluminium(III) complex with salicylidene-o-aminophenol to the fluorometric determination of nucleic acids.
Spectrochim Acta A Mol Biomol Spectrosc.    impact factor:   0
2000;  56(5): 1013-20

440:  Pillai VP, Nayar VU, Jordanovska VB.
Infrared and polarized Raman spectra of (CH3)2NH2Al(SO4)2 x 6H2O.
Spectrochim Acta A Mol Biomol Spectrosc.    impact factor:   0
2000;  56(5): 887-96

441:  Chen D, Colditz IG, Glenn GM, Tsonis CG.
Induction of systemic immune responses in sheep by topical application of cholera toxin to skin.
Vet Immunol Immunopathol.    impact factor:   0
2000;  77(3-4): 191-9

442:  Choong SK, Walkden M, Kirby R.
The management of intractable haematuria.
BJU Int.    impact factor:   0
2000;  86(9): 951-9

443:  Campbell A, Kumar A, La Rosa FG, Prasad KN, Bondy SC.
Aluminum increases levels of beta-amyloid and ubiquitin in neuroblastoma but not in glioma cells.
Proc Soc Exp Biol Med.    impact factor:   0
2000;  223(4): 397-402

444:  Viel C.
[The Norman Francois Rene Curaudau (1765-1813), pharmacist, unrecognized chemist]
Rev Hist Pharm (Paris).    impact factor:   0
2000;  48(326): 221-36

445:  Chopra N, Biswas S, Thomas B, Sabhnani L, Rao DN.
Inducing protective antibodies against ring-infected erythrocyte surface peptide antigen of Plasmodium falciparum using immunostimulating complex (ISCOMs) delivery.
Med Microbiol Immunol (Berl).    impact factor:   0
2000;  189(2): 75-83

446:  McMillan TM.
Cerebral dysfunction after water pollution incident in Camelford. Study may prolong the agony.
BMJ.    impact factor:   0
2000;  320(7245): 1338

447:  Murray V, Goodfellow F, Bogle R.
Cerebral dysfunction after water pollution incident in Camelford. Inappropriate study, inappropriate conclusions.
BMJ.    impact factor:   0
2000;  320(7245): 1338

448:  Esmonde TF.
Cerebral dysfunction after water pollution incident in Camelford. Study has several methodological errors.
BMJ.    impact factor:   0
2000;  320(7245): 1337-8

449:  Oliveira GM, Nogami EM, Nozaki J.
Biokinectic parameter investigation and biological treatment of coffee berry effluents.
Bull Environ Contam Toxicol.    impact factor:   0
2000;  64(6): 771-9

450:  He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJ.
Calcium phosphate nanoparticle adjuvant.
Clin Diagn Lab Immunol.    impact factor:   0
2000;  7(6): 899-903

451:  Horner AA, Nguyen MD, Ronaghy A, Cinman N, Verbeek S, Raz E.
DNA-based vaccination reduces the risk of lethal anaphylactic hypersensitivity in mice.
J Allergy Clin Immunol.    impact factor:   0
2000;  106(2): 349-56

452:  Su L, Tucker R, Frey SE, Gress JO, Chan IS, Kuter BJ, Guess HA.
Measuring injection-site pain associated with vaccine administration in adults: a randomised, double-blind, placebo-controlled clinical trial.
J Epidemiol Biostat.    impact factor:   0
2000;  5(6): 359-65

453:  Raz E, Spiegelberg HL.
Deviation of the allergic IgE to an IgG response by gene immunotherapy.
Int Rev Immunol.    impact factor:   0
1999;  18(3): 271-89

454:  Thomas B, Prasad A, Gokulan K, Rao DN.
Bioactive fragment of human interleukin-1beta (163-171) modulates the immune response to synthetic peptides of RESA of Plasmodium falciparum.
Med Microbiol Immunol (Berl).    impact factor:   0
1999;  187(3): 165-71

455:  Meyer W, Zschemisch NH.
Remarks on the usefulness of toluidine blue staining for RNA cytophotometry in plastic embedded tissues.
Cell Mol Biol (Noisy-le-grand).    impact factor:   0
1999;  45(4): 379-82

456:  Bugbee GJ, Elliott GC.
Effects of sucrose and dried alum sludge on the growth of Rudbeckia and leaching of nitrogen and phosphorus from potting media containing biosolids compost.
Bull Environ Contam Toxicol.    impact factor:   0
1999;  63(6): 766-73

457:  Altmann P, Cunningham J, Dhanesha U, Ballard M, Thompson J, Marsh F.
Disturbance of cerebral function in people exposed to drinking water contaminated with aluminium sulphate: retrospective study of the Camelford water incident.
BMJ.    impact factor:   0
1999;  319(7213): 807-11

458:  Ishihara T, Okamoto I, Masaki N, Kohno K, Tanimoto T, Ikegami H, Kurimoto M.
[Inhibition of antigen-specific T helper type 2 responses by Perilla frutescens extract]
Arerugi.    impact factor:   0
1999;  48(4): 443-50

459:  Wu Y, Zhou Z, Xiong Y, Wang Y, Sun J.
[Assay of aluminum content in alum and alum-processed medicinal herbs and its distribution in blood and brain in mice]
Zhongguo Zhong Yao Za Zhi.    impact factor:   0
1999;  24(2): 84-6, 125

460:  Yong TS, Lee JS, Lee IY, Park SJ, Park GM, Ree HI, Park JW, Hong CS, Park HS.
Identification of Chironomus kiiensis allergens, a dominant species of non-biting midges in Korea.
Korean J Parasitol.    impact factor:   0
1999;  37(3): 171-9

461:  Bassan N, Vinuesa M, Perez F, Roma S, Bernardi S.
[Intraepithelial enteroendocrine cells in cecum and appendix from ovoalbumin sensitized rabbits]
Acta Gastroenterol Latinoam.    impact factor:   0
1999;  29(5): 313-7

462:  Kohama Y, Akizuki O, Hagihara K, Yamada E, Yamamoto H.
Immunostimulatory oligodeoxynucleotide induces TH1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice.
J Allergy Clin Immunol.    impact factor:   0
1999;  104(6): 1231-8

463:  Katzenstein DA, Kundu S, Spritzler J, Smoller BR, Haszlett P, Valentine F, Merigan TC.
Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.
J Acquir Immune Defic Syndr.    impact factor:   0
1999;  22(4): 341-7

464:  Wen YM, Qu D, Zhou SH.
Antigen-antibody complex as therapeutic vaccine for viral hepatitis B.
Int Rev Immunol.    impact factor:   0
1999;  18(3): 251-8

465:  Shah AK, Ashtaputre AA.
Evaluation of rheological properties of the exopolysaccharide of Sphingomonas paucimobilis GS-1 for application in oil exploration.
J Ind Microbiol Biotechnol.    impact factor:   0
1999;  23(4-5): 442-445

466:  Yan M, Ye W, Song H.
[Effect of alum on intestinal microecological balance in mice]
Zhongguo Zhong Xi Yi Jie He Za Zhi.    impact factor:   0
1999;  19(9): 541-3

467:  Wu H, Tang Z, Qiu L, Ye D.
[The comparison of component contents and pharmacological actions between two kinds of processed products of Pinellia rhizoma prepared by ginger juice and alum]
Zhongguo Zhong Yao Za Zhi.    impact factor:   0
1999;  24(1): 25-8, 63

468:  Singh HP, Singh CK, Singh RR.
Effect of potash alum (aluminium potassium sulphate) on human semen and sperm.
Indian J Physiol Pharmacol.    impact factor:   0
1998;  42(2): 311-4

469:  Emanuele P, Goodman ZD.
A simple and rapid stain for copper in liver tissue.
Ann Diagn Pathol.    impact factor:   0
1998;  2(2): 125-6

470:  Jensen FC, Savary JR, Diveley JP, Chang JC.
Adjuvant activity of incomplete Freund's adjuvant.
Adv Drug Deliv Rev.    impact factor:   0
1998;  32(3): 173-186

471:  Tleugabulova D, Falcon V, Penton E.
Evidence for the denaturation of recombinant hepatitis B surface antigen on aluminium hydroxide gel.
J Chromatogr B Biomed Sci Appl.    impact factor:   0
1998;  720(1-2): 153-63

472:  Maecker HT, Do MS, Levy S.
CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses.
Proc Natl Acad Sci U S A.    impact factor:   0
1998;  95(5): 2458-62

473:  Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL.
CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.
Proc Natl Acad Sci U S A.    impact factor:   0
1998;  95(26): 15553-8

474:  Wu H, Wen H, Guo R, Ye D.
[Effect of ginger-processing on the contents of guanosine in Pinelliae rhizoma (banxia)]
Zhongguo Zhong Yao Za Zhi.    impact factor:   0
1998;  23(11): 661-3, 702-3

475:  Yan M, Song H, Zhang L, Wang Y, Wu Y, Zhou Z.
[Influence of alum on intestinal flora in mice]
Zhongguo Zhong Yao Za Zhi.    impact factor:   0
1998;  23(12): 743-5, back cover

476:  Shi Z.
[Treatment of hemorrhoid of III, IV stage by four steps injection of xiaozhiling]
Zhongguo Zhong Xi Yi Jie He Za Zhi.    impact factor:   0
1998;  18(4): 201-3

477:  Wu YH, Zhou ZM, Xiong YL, Wang YL, Sun JH, Liao HB, Luo XD.
Effects of aluminum potassium sulfate on learning, memory, and cholinergic system in mice.
Zhongguo Yao Li Xue Bao.    impact factor:   0
1998;  19(6): 509-12

478:  Shormanov SV, Ial'tsev AV.
[The use of electromagnetic field in preparing hematoxylin]
Morfologiia.    impact factor:   0
1998;  114(6): 73-4

479:  King TP, Lu G, Agosto H.
Antibody responses to bee melittin (Api m 4) and hornet antigen 5 (Dol m 5) in mice treated with the dominant T-cell epitope peptides.
J Allergy Clin Immunol.    impact factor:   0
1998;  101(3): 397-403

480:  Platts-Mills TA, Mueller GA, Wheatley LM.
Future directions for allergen immunotherapy.
J Allergy Clin Immunol.    impact factor:   0
1998;  102(3): 335-43

481:  Hirahara K, Saito S, Serizawa N, Sasaki R, Sakaguchi M, Inouye S, Taniguchi Y, Kaminogawa S, Shiraishi A.
Oral administration of a dominant T-cell determinant peptide inhibits allergen-specific TH1 and TH2 cell responses in Cry j 2-primed mice.
J Allergy Clin Immunol.    impact factor:   0
1998;  102(6 Pt 1): 961-7

482:  Bihani SN, Damle SG.
Evaluation of an alum containing mouthrinse on plaque and gingivitis inhibition over 2 weeks of supervised use.
J Indian Soc Pedod Prev Dent.    impact factor:   0
1997;  15(1): 34-8

483:  Shahi S, Kumar P, Kamboj KK, Rao DN.
Immune response against the non-repeat region (293-310) of the circumsporozoite protein of Plasmodium vivax.
Southeast Asian J Trop Med Public Health.    impact factor:   0
1997;  28(4): 748-56

484:  Wu H, Ye D, Diao H, Cai B.
[Orthogonal experiment design in the optimization of processing technology for Rhizoma Pinelliae by ginger and alum]
Zhongguo Zhong Yao Za Zhi.    impact factor:   0
1996;  21(11): 660-3, 703


Responsed in 2296 milliseconds.

Webpage designed by Dr. Xueliang Fang, last updated on 3/10/2005